View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2014	Jul. 29, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Amgen Inc.
Entity Central Index Key	0000318154
Document Type	10-Q
Document Period End Date	Jun. 30, 2014
Amendment Flag	false
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		759,607,230

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:
Product sales	$ 4,949	$ 4,595	$ 9,305	$ 8,746
Other revenues	231	84	396	171
Total revenues	5,180	4,679	9,701	8,917
Operating expenses:
Cost of sales	1,081	785	2,171	1,529
Research and development	1,018	967	2,045	1,845
Selling, general and administrative	1,136	1,256	2,159	2,414
Other	43	121	60	137
Total operating expenses	3,278	3,129	6,435	5,925
Operating income	1,902	1,550	3,266	2,992
Interest expense, net	282	241	541	504
Interest and other income, net	138	96	237	260
Income before income taxes	1,758	1,405	2,962	2,748
Provision for income taxes	211	147	342	56
Net income	$ 1,547	$ 1,258	$ 2,620	$ 2,692
Earnings per share:
Basic (in usd per share)	$ 2.04	$ 1.67	$ 3.46	$ 3.58
Diluted (in usd per share)	$ 2.01	$ 1.65	$ 3.41	$ 3.52
Shares used in calculation of earnings per share:
Basic (in shares)	759	752	758	752
Diluted (in shares)	768	764	768	764
Dividends paid per share (in usd per share)	$ 0.61	$ 0.47	$ 1.22	$ 0.94

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement of Comprehensive Income [Abstract]
Net income	$ 1,547	$ 1,258	$ 2,620	$ 2,692
Other comprehensive income (loss), net of reclassification adjustments and taxes:
Foreign currency translation gains (losses)	7	(25)	(1)	(48)
Effective portion of cash flow hedges	(25)	22	(23)	97
Net unrealized gains (losses) on available-for-sale securities	21	(205)	61	(267)
Other	0	0	1	1
Other comprehensive income (loss), net of tax	3	(208)	38	(217)
Comprehensive income	$ 1,550	$ 1,050	$ 2,658	$ 2,475

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 4,352	$ 3,805
Marketable securities	21,836	15,596
Trade receivables, net	2,697	2,697
Inventories	2,954	3,019
Other current assets	2,489	2,250
Total current assets	34,328	27,367
Property, plant and equipment, net	5,371	5,349
Intangible assets, net	13,499	13,262
Goodwill	14,844	14,968
Restricted investments	0	3,412
Other assets	1,492	1,767
Total assets	69,534	66,125
Current liabilities:
Accounts payable	982	787
Accrued liabilities	4,384	4,655
Current portion of long-term debt	2,500	2,505
Total current liabilities	7,866	7,947
Long-term debt	30,828	29,623
Other noncurrent liabilities	6,458	6,459
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding - 759.4 shares in 2014 and 754.6 shares in 2013	29,981	29,891
Accumulated deficit	(5,476)	(7,634)
Accumulated other comprehensive loss	(123)	(161)
Total stockholders’ equity	24,382	22,096
Total liabilities and stockholders’ equity	$ 69,534	$ 66,125

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Common stock and additional paid-in capital, par value (in usd per share)	$ 0.0001000000	$ 0.0001000000
Common stock and additional paid-in capital, shares authorized	2,750,000,000.0	2,750,000,000.0
Common stock and additional paid-in capital, shares outstanding	759,400,000	754,600,000

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net income	$ 2,620	$ 2,692
Depreciation and amortization	1,024	554
Stock-based compensation expense	199	204
Other items, net	1	135
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net	0	(133)
Inventories	40	(34)
Other assets	(11)	88
Accounts payable	125	117
Accrued income taxes	(131)	(592)
Other liabilities	(498)	(382)
Net cash provided by operating activities	3,369	2,649
Cash flows from investing activities:
Purchases of property, plant and equipment	(345)	(317)
Cash paid for acquisitions, net of cash acquired	(115)	0
Purchases of marketable securities	(15,593)	(10,774)
Proceeds from sales of marketable securities	9,137	10,968
Proceeds from maturities of marketable securities	3,295	3,941
Change in restricted investments	533	0
Other	(135)	(50)
Net cash (used in) provided by investing activities	(3,223)	3,768
Cash flows from financing activities:
Net proceeds from issuance of debt	4,476	0
Repayment of debt	(3,355)	(2,500)
Repurchases of common stock	0	(832)
Dividends paid	(923)	(707)
Net proceeds from issuance of common stock in connection with the Company’s equity award programs	99	212
Other	104	(41)
Net cash provided by (used in) financing activities	401	(3,868)
Increase in cash and cash equivalents	547	2,549
Cash and cash equivalents at beginning of period	3,805	3,257
Cash and cash equivalents at end of period	$ 4,352	$ 5,806

Summary of significant accounting policies	6 Months Ended
Summary of significant accounting policies	Jun. 30, 2014
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics. Basis of presentation The financial information for the three and six months ended June 30, 2014 and 2013, is unaudited but includes all adjustments (consisting of only normal recurring adjustments, unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2013 and in our Quarterly Report on Form 10-Q for the period ended March 31, 2014. Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $7.2 billion and $6.9 billion as of June 30, 2014, and December 31, 2013, respectively. Restricted investments As of December, 31, 2013, we had restricted investments on our Condensed Consolidated Balance Sheet that were owned by ATL Holdings Limited (ATL Holdings), a wholly-owned subsidiary. ATL Holdings was an entity distinct from the Company and its other subsidiaries, with separate assets and liabilities. Because certain third parties owned Class A preferred shares of ATL Holdings, this entity was required to hold restricted investments, which were composed of interest-bearing securities, cash and related interest receivable as of December 31, 2013. On May 22, 2014, the Company repurchased all of the outstanding Class A preferred shares, and therefore, there were no remaining restricted investments on our Condensed Consolidated Balance Sheet as of June 30, 2014. See Note 8, Financing arrangements. Recent accounting pronouncements In May 2014, a new accounting standard was issued that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. This new standard will be effective for interim and annual periods beginning January 1, 2017, and is required to be adopted retrospectively. We are currently evaluating the impact this new standard will have on our financial statements.

Business combinations

6 Months Ended

Jun. 30, 2014

Business Combinations [Abstract]

Business combinations

Onyx Pharmaceuticals

On October 1, 2013, we acquired all of the outstanding stock of Onyx Pharmaceuticals, Inc. (Onyx), a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people afflicted with cancer. Onyx has a multiple myeloma franchise, with Kyprolis^® (carfilzomib) for Injection already approved in the United States, and with oprozomib being evaluated in clinical trials for patients with hematologic malignancies. In addition, Onyx has three partnered oncology assets: Nexavar^® (sorafenib) tablets (an Onyx and Bayer compound), Stivarga^® (regorafenib) tablets (a Bayer compound), and palbociclib (a Pfizer, Inc. compound). This transaction, which was accounted for as a business combination, provides us with an opportunity to expand our oncology franchise. Onyx’s operations have been included in our condensed consolidated financial statements commencing on the acquisition date.

The aggregate consideration to acquire Onyx was paid in cash and consisted of (in millions):



Total consideration transferred	$	9,517
Compensation expense	197
Total cash paid	$	9,714

The $9,517 million cash payment consisted of a $9,186 million cash payment to the outstanding common stockholders and a $331 million cash payment to the Onyx equity award holders for services rendered prior to October 1, 2013 under the Onyx equity award plans. The remaining $197 million of cash, which related to the accelerated vesting of the remaining Onyx equity awards, was recognized as compensation expense during the three months ended December 31, 2013. This amount was included primarily in Selling, general and administrative (SG&A) expense in the Consolidated Statement of Income.

The consideration to acquire Onyx was allocated preliminarily to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):



Cash and cash equivalents	$	319
Marketable securities	337
Inventories	170
Indefinite-lived intangible assets - In-process research and development (IPR&D)	1,180
Finite-lived intangible assets - Developed product technology rights	6,190
Finite-lived intangible assets - Licensing rights	2,792
Goodwill	2,388
Convertible debt	(742		)
Assumed contingent consideration	(261		)
Deferred income taxes, net	(2,996		)
Other assets (liabilities), net	140
Total consideration	$	9,517

Onyx’s preliminary goodwill at December 31, 2013 has been revised. Goodwill was reduced by $138 million due primarily to revisions which increased the acquisition date fair values of developed product technology rights by $280 million and deferred income taxes by $78 million, and decreased inventory by $80 million. The adjustments did not have a material effect on our current or prior period financial statements.

The developed product technology rights acquired relate to Kyprolis^® which is approved in the United States. This product technology is being amortized on a straight-line basis over the estimated useful life of 12 years.

Licensing rights acquired represent the aggregate estimated fair values of receiving future milestone, royalty and/or profit sharing payments associated with various contract agreements that were entered into by Onyx prior to the acquisition. The weighted-average useful life of these finite-lived intangible assets is ten years, and they are being amortized on a straight-line basis.

Our accounting for this acquisition is preliminary. The fair value estimates for the assets acquired and liabilities assumed were based upon preliminary calculations and valuations, and our estimates and assumptions are subject to change as we obtain additional information for our estimates during the measurement period (up to one year from the acquisition date). The primary areas of those preliminary estimates that are not yet finalized relate to certain tax matters.

Filgrastim and pegfilgrastim rights acquisition

In October 2013, we entered into an agreement to acquire the licenses to filgrastim and pegfilgrastim effective January 1, 2014 (acquisition date), that were held by F. Hoffmann-La Roche Ltd. (Roche) in approximately 100 markets in Eastern Europe, Latin America, Asia, the Middle East and Africa (Product Rights), and to settle our preexisting relationship related to the Product Rights for total consideration of $497 million. The acquisition of the Product Rights was accounted for as a business combination as the acquired rights and processes are capable of producing an immediate return to us, and the settlement of the preexisting relationship was accounted for separately from the business combination.

This transaction provides us with an opportunity to expand our geographic presence and reach more patients in more countries that could benefit from our therapies. The operations of the acquired set of activities have been included in our financial statements commencing on the acquisition date. Pro forma results of operations for this acquisition have not been presented because this acquisition is not material to our consolidated results of operations.

The aggregate consideration transferred consisted of (in millions):



Total consideration transferred or to be transferred	$	497
Settlement of preexisting relationship at fair value	(99		)
Total consideration transferred to acquire the Product Rights	$	398

The settlement of the preexisting relationship relates to a supply contract between Amgen and Roche that was terminated as a result of the acquisition of the Product Rights. The fair value of the contract of $99 million was recognized in Cost of sales in the Condensed Consolidated Statement of Income for the six months ended June 30, 2014.

The consideration to acquire the Product Rights was allocated to the acquisition date fair values of assets acquired as follows (in millions):



Finite-lived intangible assets - Marketing-related rights	$	363
Finite-lived intangible assets - Developed product technology rights	11
Goodwill	3
Other assets	21
Total consideration	$	398

The marketing-related and developed product technology rights acquired relate to the Product Rights and are being amortized on a straight-line basis over their estimated useful lives of five years and three and one-half years, respectively.

Our accounting for this acquisition is preliminary. The fair value estimates for the assets acquired and liabilities incurred were based upon preliminary calculations and valuations, and our estimates and assumptions are subject to change as we obtain additional information for our estimates during the measurement period (up to one year from the acquisition date). The primary areas of those preliminary estimates that are not yet finalized relate to certain tangible assets and liabilities incurred, and identifiable intangible assets.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Income taxes	6 Months Ended
Income taxes	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The effective tax rates for the three and six months ended June 30, 2014 were 12.0% and11.5%, respectively, compared with 10.5% and 2.0% for the corresponding periods of the prior year. The effective rates are different from the federal statutory rates primarily as a result of indefinitely invested earnings of our foreign operations. We do not provide for U.S. income taxes on undistributed earnings of our foreign operations that are intended to be invested indefinitely outside of the United States. In addition, the effective tax rates for both periods were reduced by foreign tax credits associated with the Puerto Rico excise tax described below. The increase in our effective tax rate for the three months ended June 30, 2014, is due primarily to the exclusion of the benefit of the research and development (R&D) tax credit, which expired as of December 31, 2013, and was not reinstated as of June 30, 2014. The increase was offset partially by the favorable tax impact of changes in the jurisdictional mix of income and expenses due primarily to higher domestic acquisition-related expenses during the three months ended June 30, 2014. The effective tax rate for the six months ended June 30, 2014, increased due primarily to two significant events that occurred during the three months ended March 31, 2013. First, we settled our examination with the Internal Revenue Service (IRS) for the years ended December 31, 2007, 2008 and 2009 in which we agreed to certain adjustments proposed by the IRS and remeasured our unrecognized tax benefits (UTBs) accordingly. Second, the American Taxpayer Relief Act of 2012, enacted during the first quarter of 2013, reinstated the federal R&D tax credit for 2012 and 2013. Therefore, our effective tax rate for the six months ended June 30, 2013, included a benefit for the full-year 2012 R&D tax credit, recorded as a discrete item in the first quarter of 2013. The increase was offset partially by the favorable tax impact of changes in the jurisdictional mix of income and expenses due primarily to higher domestic acquisition-related expenses in 2014. Puerto Rico imposes an excise tax on the gross intercompany purchase price of goods and services from our manufacturing subsidiary in Puerto Rico. The rate was 2.75% in the first half of 2013 and 4.0% effective July 1, 2013 through December 31, 2017. We account for the excise tax as a manufacturing cost that is capitalized in inventory and expensed in cost of sales when the related products are sold. For U.S. income tax purposes, the excise tax results in foreign tax credits that are generally recognized in our provision for income taxes when the excise tax is incurred. Excluding the impact of the Puerto Rico excise tax, our effective tax rates for the three and six months ended June 30, 2014, would have been 16.7% and 16.2%, respectively, compared with 15.6% and 7.5% for the corresponding periods of the prior year. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely audited by the tax authorities in those jurisdictions. Significant disputes may arise with these tax authorities involving issues of the timing and amount of income and deductions, the use of tax credits and allocations of income among various tax jurisdictions because of differing interpretations of tax laws and regulations. We are no longer subject to U.S. federal income tax examinations for years ending on or before December 31, 2009, or to California state income tax examinations for years ending on or before December 31, 2005. During the three and six months ended June 30, 2014, the gross amount of our UTBs increased by approximately $100 million and $165 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of June 30, 2014, if recognized, would affect our effective tax rate. As of June 30, 2014, we believe it is reasonably possible that our gross liabilities for UTBs may decrease by approximately $70 million within the succeeding 12 months due to the resolution of state audits.

Earnings per share

6 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Earnings per share

The computation of basic earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which include principally shares that may be issued under our stock option awards and restricted stock and performance unit awards, determined using the treasury stock method (collectively “dilutive securities”).

The computation for basic and diluted EPS was as follows (in millions, except per share data):



	Three months ended				Six months ended
	June 30,				June 30,
	2014		2013		2014		2013
Income (Numerator):
Net income for basic and diluted EPS	$	1,547	$	1,258	$	2,620	$	2,692

Shares (Denominator):
Weighted-average shares for basic EPS	759		752		758		752
Effect of dilutive securities	9		12		10		12
Weighted-average shares for diluted EPS	768		764		768		764

Basic EPS	$	2.04	$	1.67	$	3.46	$	3.58
Diluted EPS	$	2.01	$	1.65	$	3.41	$	3.52

For the three and six months ended June 30, 2014 and 2013, the number of anti-dilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.

Available-for-sale investments

6 Months Ended

Jun. 30, 2014

Investments, Debt and Equity Securities [Abstract]

Available-for-sale investments

The amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security were as follows (in millions):



Type of security as of June 30, 2014	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value
U.S. Treasury securities	$	2,886	$	5	$	(2	)	$	2,889
Other government-related debt securities:
U.S.	963		1		(3		)	961
Foreign and other	1,547		26		(9		)	1,564
Corporate debt securities:
Financial	5,131		35		(3		)	5,163
Industrial	5,337		46		(10		)	5,373
Other	570		5		(1		)	574
Residential mortgage-backed securities	1,746		5		(11		)	1,740
Other mortgage- and asset-backed securities	1,926		1		(53		)	1,874
Money market mutual funds	3,328		—		—			3,328
Other short-term interest-bearing securities	2,138		—		—			2,138
Total interest-bearing securities	25,572		124		(92		)	25,604
Equity securities	86		—		(4		)	82
Total available-for-sale investments	$	25,658	$	124	$	(96	)	$	25,686



Type of security as of December 31, 2013	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value
U.S. Treasury securities	$	4,737	$	2	$	(9	)	$	4,730
Other government-related debt securities:
U.S.	1,087		—		(8		)	1,079
Foreign and other	1,574		13		(41		)	1,546
Corporate debt securities:
Financial	3,667		28		(19		)	3,676
Industrial	3,745		36		(21		)	3,760
Other	388		4		(2		)	390
Residential mortgage-backed securities	1,478		3		(21		)	1,460
Other mortgage- and asset-backed securities	1,555		1		(45		)	1,511
Money market mutual funds	3,366		—		—			3,366
Other short-term interest-bearing securities	750		—		—			750
Total interest-bearing securities	22,347		87		(166		)	22,268
Equity securities	85		10		—			95
Total available-for-sale investments	$	22,432	$	97	$	(166	)	$	22,363

The fair values of available-for-sale investments by classification in the Condensed Consolidated Balance Sheets were as follows (in millions):



Classification in the Condensed Consolidated Balance Sheets	June 30, 2014		December 31, 2013
Cash and cash equivalents	$	3,768	$	3,266
Marketable securities	21,836		15,596
Other assets — noncurrent	82		95
Restricted investments	—		3,406
Total available-for-sale investments	$	25,686	$	22,363

Cash and cash equivalents in the table above excludes cash of $584 million and $539 million as of June 30, 2014, and December 31, 2013, respectively. Restricted investments in the table above excludes $6 million of interest receivable as of December 31, 2013.

The fair values of available-for-sale interest-bearing security investments by contractual maturity, except for mortgage- and asset- backed securities that do not have a single maturity date, were as follows (in millions):



Contractual maturity	June 30, 2014		December 31, 2013
Maturing in one year or less	$	5,820	$	6,799
Maturing after one year through three years	5,927		4,785
Maturing after three years through five years	7,394		6,057
Maturing after five years through ten years	2,671		1,656
Maturing after ten years	178		—
Mortgage- and asset-backed securities	3,614		2,971
Total interest-bearing securities	$	25,604	$	22,268

For the three months ended June 30, 2014 and 2013, realized gains totaled $57 million and $33 million, respectively, and realized losses totaled $17 million and $26 million, respectively. For the six months ended June 30, 2014 and 2013, realized gains totaled $85 million and $118 million, respectively, and realized losses totaled $43 million and $44 million, respectively. The cost of securities sold is based on the specific identification method.

The unrealized losses on available-for-sale investments and their related fair values were as follows (in millions):



	Less than 12 months					12 months or greater
Type of security as of June 30, 2014	Fair value		Unrealized losses			Fair value		Unrealized losses
U.S. Treasury securities	$	700	$	(1	)	$	280	$	(1	)
Other government-related debt securities:
U.S.	—		—			323		(3		)
Foreign and other	148		(2		)	277		(7		)
Corporate debt securities:
Financial	1,047		(2		)	134		(1		)
Industrial	1,831		(9		)	130		(1		)
Other	126		(1		)	—		—
Residential mortgage-backed securities	459		(3		)	462		(8		)
Other mortgage- and asset-backed securities	514		(5		)	860		(48		)
Equity securities	16		(4		)	—		—
Total	$	4,841	$	(27	)	$	2,466	$	(69	)



	Less than 12 months					12 months or greater
Type of security as of December 31, 2013	Fair value		Unrealized losses			Fair value		Unrealized losses
U.S. Treasury securities	$	2,362	$	(9	)	$	—	$	—
Other government-related debt securities:
U.S.	789		(8		)	—		—
Foreign and other	986		(38		)	39		(3		)
Corporate debt securities:
Financial	1,781		(19		)	—		—
Industrial	1,543		(21		)	1		—
Other	182		(2		)	—		—
Residential mortgage-backed securities	794		(14		)	257		(7		)
Other mortgage- and asset-backed securities	982		(29		)	313		(16		)
Total	$	9,419	$	(140	)	$	610	$	(26	)

The primary objective of our investment portfolio is to enhance overall returns in an efficient manner while maintaining safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer.

We review our available-for-sale investments for other-than-temporary declines in fair value below our cost basis each quarter and whenever events or changes in circumstances indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below our cost basis and adverse conditions related specifically to the security, including any changes to the credit rating of the security. As of June 30, 2014, and December 31, 2013, we believe the cost bases for our available-for-sale investments were recoverable in all material respects.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Inventories

6 Months Ended

Jun. 30, 2014

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following (in millions):



	June 30, 2014		December 31, 2013
Raw materials	$	202	$	217
Work in process	1,836		2,064
Finished goods	916		738
Total inventories	$	2,954	$	3,019

Goodwill and other intangible assets

6 Months Ended

Jun. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and other intangible assets

Goodwill

The changes in the carrying amounts of goodwill were as follows (in millions):



	Six months ended June 30,
	2014			2013
Beginning balance	$	14,968		$	12,662
Goodwill related to acquisitions of businesses⁽¹⁾	(128		)	(46		)
Currency translation adjustments	4			(38		)
Ending balance	$	14,844		$	12,578


⁽¹⁾	Composed primarily of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in business combinations recorded during their respective measurement periods.

Identifiable intangible assets

Identifiable intangible assets consisted of the following (in millions):



	June 30, 2014							December 31, 2013
	Gross carrying amount		Accumulated amortization			Intangible assets, net		Gross carrying amount		Accumulated amortization			Intangible assets, net
Finite-lived intangible assets:
Developed product technology rights	$	10,421	$	(3,753	)	$	6,668	$	10,130	$	(3,347	)	$	6,783
Licensing rights	3,241		(543		)	2,698		3,241		(366		)	2,875
R&D technology rights	1,206		(538		)	668		1,207		(496		)	711
Marketing-related rights	1,251		(439		)	812		619		(366		)	253
Total finite-lived intangible assets	16,119		(5,273		)	10,846		15,197		(4,575		)	10,622
Indefinite-lived intangible assets:
IPR&D	2,653		—			2,653		2,640		—			2,640
Total identifiable intangible assets	$	18,772	$	(5,273	)	$	13,499	$	17,837	$	(4,575	)	$	13,262

Developed product technology rights consist of rights related to marketed products acquired in business combinations. Licensing rights are composed primarily of intangible assets acquired as part of the acquisition of Onyx (see Note 2, Business combinations), capitalized payments to third parties for milestones related to regulatory approvals to commercialize products and up-front payments associated with royalty obligations for marketed products. R&D technology rights consist of technology used in R&D with alternative future uses. Marketing-related intangible assets are composed primarily of rights related to the sale and distribution of marketed products, including assets purchased from the Glaxo Group Limited (Glaxo) discussed below and licenses to filgrastim and pegfilgrastim acquired from Roche (see Note 2, Business combinations).

On April 1, 2014, we entered into a Termination and Transition Agreement (the Transition Agreement) with Glaxo which terminated, in part, and amended, in part, our agreement with Glaxo (the Collaboration Agreement) for the commercialization of denosumab for osteoporosis indications in certain geographic territories, including the European Union (EU), Switzerland, Australia, Norway, Russia and Mexico. The Transition Agreement terminated the Collaboration Agreement for all countries and regions, except for Australia. All commercial activities assigned to Glaxo under the Collaboration Agreement other than those in Australia will be transitioned back to us no later than December 31, 2014. In exchange for the early termination (except Australia) of the Collaboration Agreement, we will make payments to Glaxo totaling $275 million, which represents the reacquisition of a previously shared economic interest in geographic territories where we were already marketing denosumab and accordingly, the transaction was accounted for as an acquisition of identifiable intangible assets.

The Transition Agreement does not change the terms of the related Expansion Agreement under which Glaxo will commercialize denosumab for all indications in certain other geographic territories.

IPR&D consists of R&D projects acquired in a business combination which are not complete due to remaining technological risks and/or lack of receipt of the required regulatory approvals. These projects include Kyprolis^®, a treatment for multiple myeloma being developed for use outside the United States (excluding Japan) acquired in the Onyx transaction (see Note 2, Business combinations); AMG 416 (formerly known as velcalcetide), a treatment for secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis; blinatumomab, a treatment for acute lymphoblastic leukemia (ALL), and talimogene laherparepvec, a treatment for melanoma.

For all IPR&D projects, there are major risks and uncertainties associated with the timely and successful completion of development and commercialization of these product candidates, including our ability to confirm their safety and efficacy based on data from clinical trials, our ability to obtain necessary regulatory approvals and our ability to successfully complete these tasks within budgeted costs. We are not able to market a human therapeutic without obtaining regulatory approvals, and such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. In addition, the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans, impact the revenues a product can generate. Consequently, the eventual realized value, if any, of these acquired IPR&D projects may vary from their estimated fair values.

During the three months ended June 30, 2014 and 2013, we recognized amortization charges associated with our finite-lived intangible assets of $341 million and $119 million, respectively. During the six months ended June 30, 2014 and 2013, we recognized amortization charges associated with our finite-lived intangible assets of $698 million and $236 million, respectively. The total estimated amortization charges for our finite-lived intangible assets for the six months ended December 31, 2014, and the years ended December 31, 2015, 2016, 2017, 2018 and 2019, are $670 million, $1.3 billion, $1.3 billion, $1.2 billion, $999 million and $926 million, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Financing arrangements

6 Months Ended

Jun. 30, 2014

Debt Disclosure [Abstract]

Financing arrangements

The carrying values and the fixed contractual coupon rates, as applicable, of our long-term borrowings were as follows (in millions):



	June 30, 2014			December 31, 2013
1.875% notes due 2014 (1.875% 2014 Notes)	$	1,000		$	1,000
4.85% notes due 2014 (4.85% 2014 Notes)	1,000			1,000
2.30% notes due 2016 (2.30% 2016 Notes)	749			749
2.50% notes due 2016 (2.50% 2016 Notes)	1,000			999
Floating Rate Notes due 2017	600			—
1.25% notes due 2017 (1.25% 2017 Notes)	849			—
2.125% notes due 2017 (2.125% 2017 Notes)	1,249			1,248
5.85% notes due 2017 (5.85% 2017 Notes)	1,099			1,099
6.15% notes due 2018 (6.15% 2018 Notes)	500			500
Master Repurchase Agreement obligation due 2018	—			3,100
Term Loan due 2018	4,625			4,875
4.375% euro-denominated notes due 2018 (4.375% 2018 euro Notes)	748			751
Floating Rate Notes due 2019	250			—
2.20% notes due 2019 (2.20% 2019 Notes)	1,397			—
5.70% notes due 2019 (5.70% 2019 Notes)	999			999
2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes)	922			925
4.50% notes due 2020 (4.50% 2020 Notes)	300			300
3.45% notes due 2020 (3.45% 2020 Notes)	898			898
4.10% notes due 2021 (4.10% 2021 Notes)	998			998
3.875% notes due 2021 (3.875% 2021 Notes)	1,746			1,746
3.625% notes due 2022 (3.625% 2022 Notes)	747			747
3.625% notes due 2024 (3.625% 2024 Notes)	1,398			—
5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes)	807			781
4.00% pound-sterling-denominated notes due 2029 (4.00% 2029 pound sterling Notes)	1,183			1,144
6.375% notes due 2037 (6.375% 2037 Notes)	899			899
6.90% notes due 2038 (6.90% 2038 Notes)	499			499
6.40% notes due 2039 (6.40% 2039 Notes)	996			996
5.75% notes due 2040 (5.75% 2040 Notes)	697			697
4.95% notes due 2041 (4.95% 2041 Notes)	596			596
5.15% notes due 2041 (5.15% 2041 Notes)	2,233			2,233
5.65% notes due 2042 (5.65% 2042 Notes)	1,244			1,244
5.375% notes due 2043 (5.375% 2043 Notes)	1,000			1,000
Other notes	100			105
Total debt	33,328			32,128
Less current portion	(2,500		)	(2,505		)
Total noncurrent debt	$	30,828		$	29,623

Debt repayments

During the six months ended June 30, 2014, we repurchased all of the Class A preferred shares of ATL Holdings that were subject to a Master Repurchase Agreement for $3.1 billion. We also repaid $250 million of principal on our Term Loan Credit Facility and $5 million of Other notes.

Debt issuances

In May 2014, we issued $4.5 billion aggregate principal amount of notes, comprised of the Floating Rate Notes due 2017, the 1.25% 2017 Notes, the Floating Rate Notes due 2019, the 2.20% 2019 Notes and the 3.625% 2024 Notes. The Floating Rate Notes due in 2017 and 2019 bear interest equal to three-month London Interbank Offered Rates (LIBOR) plus 0.38% and three-month LIBOR plus 0.60%, respectively, and are not subject to redemption at our option. The fixed rate notes that were issued may be redeemed at any time at our option, in whole or in part, at the principal amount of the notes being redeemed plus accrued and unpaid interest and, except as discussed below, a “make-whole” amount, as defined. The 2.20% 2019 Notes and 3.625% 2024 Notes may be redeemed without payment of a "make-whole" amount if they are redeemed on or after one month or three months, respectively, prior to their maturity dates. In the event of a change in control triggering event, as defined, we may be required to purchase all or a portion of the notes at a price equal to 101% of the principal amount of the notes plus accrued and unpaid interest. Debt issuance costs incurred in connection with the issuance of these notes totaling approximately $18 million are being amortized over the respective lives of the notes, and the related charge is included in Interest expense, net in the Condensed Consolidated Statements of Income.

Stockholders' equity

6 Months Ended

Jun. 30, 2014

Equity [Abstract]

Stockholders' equity

Stockholders’ equity

Stock repurchase program

We had no repurchases under our stock repurchase program during the six months ended June 30, 2014. As of June 30, 2014, $1.6 billion remained available under our Board of Directors-approved stock repurchase program.

Dividends

On December 13, 2013, the Board of Directors declared a quarterly cash dividend of $0.61 per share of common stock, which was paid on March 7, 2014. On March 5, 2014, the Board of Directors declared a quarterly cash dividend of $0.61 per share of common stock, which was paid on June 6, 2014. On July 25, 2014, the Board of Directors declared a quarterly cash dividend of $0.61 per share of common stock, which will be paid on September 5, 2014, to all stockholders of record as of the close of business on August 14, 2014.

Accumulated other comprehensive income

The components of accumulated other comprehensive income (AOCI) were as follows (in millions):



	Foreign currency translation			Cash flow hedges			Available-for-sale securities			Other			AOCI
Balance as of December 31, 2013	$	(68	)	$	(33	)	$	(43	)	$	(17	)	$	(161	)
Foreign currency translation adjustments	(12		)	—			—			—			(12		)
Unrealized gains	—			17			66			1			84
Reclassification adjustments to income	—			(14		)	(2		)	—			(16		)
Income taxes	4			(1		)	(24		)	—			(21		)
Balance as of March 31, 2014	$	(76	)	$	(31	)	$	(3	)	$	(16	)	$	(126	)
Foreign currency translation adjustments	9			—			—			—			9
Unrealized gains	—			8			73			—			81
Reclassification adjustments to income	—			(48		)	(40		)	—			(88		)
Income taxes	(2		)	15			(12		)	—			1
Balance as of June 30, 2014	$	(69	)	$	(56	)	$	18		$	(16	)	$	(123	)

The reclassifications out of AOCI to Net income were as follows (in millions):



	Amounts reclassified out of AOCI
Components of AOCI	Three months ended June 30, 2014			Three months ended June 30, 2013			Line item affected in the Statements of Income
Cash flow hedges:
Foreign currency contract gains	$	—		$	7		Product sales
Cross-currency swap contract gains	48			12			Interest and other income, net
Forward interest rate contract losses	—			(1		)	Interest expense, net
	48			18			Total before income tax
	(18		)	(7		)	Tax expense
	$	30		$	11		Net of taxes
Available-for-sale securities:
Net realized gains	$	40		$	7		Interest and other income, net
	(15		)	(3		)	Tax expense
	$	25		$	4		Net of taxes



	Amounts reclassified out of AOCI
Components of AOCI	Six months ended June 30, 2014			Six months ended June 30, 2013			Line item affected in the Statements of Income
Cash flow hedges:
Foreign currency contract gains	$	—		$	3		Product sales
Cross-currency swap contract gains (losses)	62			(128		)	Interest and other income, net
Forward interest rate contract losses	—			(1		)	Interest expense, net
	62			(126		)	Total before income tax
	(23		)	46			Tax (expense)/benefit
	$	39		$	(80	)	Net of taxes
Available-for-sale securities:
Net realized gains	$	42		$	74		Interest and other income, net
	(16		)	(28		)	Tax expense
	$	26		$	46		Net of taxes

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Fair value measurement

6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair value measurement

To estimate the fair value of our financial assets and liabilities we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the source of inputs as follows:



Level 1	—	Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access
Level 2	—	Valuations for which all significant inputs are observable, either directly or indirectly, other than level 1 inputs
Level 3	—	Valuations based on inputs that are unobservable and significant to the overall fair value measurement

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.

The fair value of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis was as follows (in millions):



	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Fair value measurement
as of June 30, 2014, using:							Total
Assets:
Available-for-sale investments:
U.S. Treasury securities	$	2,889	$	—	$	—	$	2,889
Other government-related debt securities:
U.S.	—		961		—		961
Foreign and other	—		1,564		—		1,564
Corporate debt securities:
Financial	—		5,163		—		5,163
Industrial	—		5,373		—		5,373
Other	—		574		—		574
Residential mortgage-backed securities	—		1,740		—		1,740
Other mortgage- and asset-backed securities	—		1,874		—		1,874
Money market mutual funds	3,328		—		—		3,328
Other short-term interest-bearing securities	—		2,138		—		2,138
Equity securities	82		—		—		82
Derivatives:
Foreign currency contracts	—		32		—		32
Cross-currency swap contracts	—		214		—		214
Interest rate swap contracts	—		30		—		30
Total assets	$	6,299	$	19,663	$	—	$	25,962

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	83	$	—	$	83
Cross-currency swap contracts	—		1		—		1
Interest rate swap contracts	—		66		—		66
Contingent consideration obligations in connection with business combinations	—		—		610		610
Total liabilities	$	—	$	150	$	610	$	760



	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Fair value measurement
as of December 31, 2013, using:							Total
Assets:
Available-for-sale investments:
U.S. Treasury securities	$	4,730	$	—	$	—	$	4,730
Other government-related debt securities:
U.S.	—		1,079		—		1,079
Foreign and other	—		1,546		—		1,546
Corporate debt securities:
Financial	—		3,676		—		3,676
Industrial	—		3,760		—		3,760
Other	—		390		—		390
Residential mortgage-backed securities	—		1,460		—		1,460
Other mortgage- and asset-backed securities	—		1,511		—		1,511
Money market mutual funds	3,366		—		—		3,366
Other short-term interest-bearing securities	—		750		—		750
Equity securities	95		—		—		95
Derivatives:
Foreign currency contracts	—		53		—		53
Cross-currency swap contracts	—		193		—		193
Total assets	$	8,191	$	14,418	$	—	$	22,609

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	107	$	—	$	107
Cross-currency swap contracts	—		4		—		4
Interest rate swap contracts	—		161		—		161
Contingent consideration obligations in connection with business combinations	—		—		595		595
Total liabilities	$	—	$	272	$	595	$	867

The fair values of our U.S. Treasury securities, money market mutual funds and equity securities are based on quoted market prices in active markets with no valuation adjustment.

Most of our other government-related and corporate debt securities are investment grade with maturity dates of five years or less from the balance sheet date. Our other government-related debt securities portfolio is composed of securities with weighted-average credit ratings of A by Standard & Poor's Financial Services LLC (S&P), A+ by Moody's Investor Service, Inc. (Moody's) or Fitch, Inc. (Fitch); and our corporate debt securities portfolio has a weighted-average credit rating of BBB+ by S&P or Moody's, and A- by Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; and other observable inputs.

Our residential mortgage-, other mortgage- and asset-backed securities portfolio is composed entirely of senior tranches, with credit ratings of AAA by S&P, Moody's or Fitch. We estimate the fair values of these securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.

We value our other short-term interest-bearing securities at amortized cost, which approximates fair value given their near term maturity dates.

All of our foreign currency forward and option derivatives contracts have maturities of three years or less and all are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimated the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency rates, LIBOR cash and swap rates and obligor credit default swap rates. In addition, inputs for our foreign currency option contracts also include implied volatility measures. These inputs, where applicable, are at commonly quoted intervals. See Note 11, Derivative instruments.

Our cross-currency swap contracts are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimated the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs include foreign currency exchange rates, LIBOR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. See Note 11, Derivative instruments.

Our interest rate swap contracts are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimated the fair values of these contracts by using an income-based industry standard valuation model for which all significant inputs were observable either directly or indirectly. These inputs included LIBOR, swap rates and obligor credit default swap rates.

Contingent consideration obligations

We have incurred contingent consideration obligations as the result of our acquisition of a business and upon the assumption of contingent consideration obligations incurred by an acquired company discussed below. These contingent consideration obligations are recorded at their estimated fair values, and we revalue these obligations each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to product candidates acquired in the business combinations and are reviewed quarterly by management in our R&D and commercial sales organizations. These inputs include, as applicable, estimated probabilities and timing of achieving specified regulatory and commercial milestones and estimated annual sales. Significant changes which increase or decrease the probabilities of achieving the related regulatory and commercial events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of these obligations, as applicable. Changes in fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.

The changes in carrying amounts of contingent consideration obligations were as follows (in millions):



	Three months ended June 30,				Six months ended June 30,
	2014		2013		2014		2013
Beginning balance	$	596	$	222	$	595	$	221
Net changes in valuation	14		110		15		111
Ending balance	$	610	$	332	$	610	$	332

As a result of our acquisition of BioVex Group, Inc. (BioVex) in March 2011, we are obligated to pay its former shareholders up to $575 million of additional consideration contingent upon achieving separate regulatory and sales-related milestones with regard to talimogene laherparepvec, which was acquired in the acquisition and is currently in clinical development for the treatment of melanoma. The three largest of these potential payments are $125 million each, including the amounts due: (i) upon the filing of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), (ii) upon the first commercial sale in the United States following receipt of marketing approval for use of the product in specified patient populations and (iii) upon achievement of an agreed level of worldwide sales within a specified period of time. Up to $200 million of additional consideration is due in payments of varying amounts upon achievement of certain other regulatory and sales-related milestones.

We estimate the fair values of the obligations to the former shareholders of BioVex by using a combination of probability-adjusted discounted cash flows, option pricing techniques and a simulation model of expected annual sales. In July 2014, we submitted a BLA in the United States for regionally and distantly metastatic melanoma. As a result of our quarterly review of the key assumptions, the estimated aggregate fair value of the contingent consideration obligations increased by $13 million during the three months ended June 30, 2014 to a fair value of $347 million as of June 30, 2014.

We assumed contingent consideration obligations upon the acquisition of Onyx arising from Onyx's 2009 acquisition of Proteolix, Inc. There are two separate milestone payments of $150 million each which would be triggered if Kyprolis^® receives specified marketing approvals for relapsed multiple myeloma on or before March 31, 2016, by each of the FDA and the European Medicines Agency. We estimate the fair values of contingent obligations to the former shareholders of Proteolix, Inc. by using probability-adjusted discounted cash flows. The estimated aggregate fair value of the contingent consideration obligations increased by $1 million and $2 million during the three and six months ended June 30, 2014, respectively, to a fair value of $263 million as of June 30, 2014.

There have been no transfers of assets or liabilities between the fair value measurement levels, and there were no material remeasurements to fair value during the six months ended June 30, 2014 and 2013, of assets and liabilities that are not measured at fair value on a recurring basis.

Summary of the fair value of other financial instruments

Cash equivalents

The estimated fair values of cash equivalents approximate their carrying values due to the short-term nature of these financial instruments.

Borrowings

We estimated the fair value of our long-term debt (Level 2) by taking into consideration indicative prices obtained from a third-party financial institution that utilizes industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable either directly or indirectly. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; credit spreads; benchmark yields; foreign currency exchange rates, as applicable; and other observable inputs. As of June 30, 2014, and December 31, 2013, the aggregate fair values of our long-term debt were $35.6 billion and $33.5 billion, respectively, and the carrying values were $33.3 billion and $32.1 billion, respectively.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Derivative instruments

6 Months Ended

Jun. 30, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative instruments

The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to these exposures, we utilize or have utilized certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We do not use derivatives for speculative trading purposes.

Cash flow hedges

We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, associated primarily with our euro-denominated international product sales. Increases and decreases in the cash flows associated with our international product sales due to movements in foreign currency exchange rates are offset partially by the corresponding increases and decreases in our international operating expenses resulting from these foreign currency exchange rate movements. To further reduce our exposure to foreign currency exchange rate fluctuations on our international product sales, we enter into foreign currency forward and option contracts to hedge a portion of our projected international product sales primarily over a three-year time horizon, with, at any given point in time, a higher percentage of nearer-term projected product sales being hedged than in successive periods. As of June 30, 2014, and December 31, 2013, we had open foreign currency forward contracts with notional amounts of $4.0 billion and open foreign currency option contracts with notional amounts of $342 million and $516 million, respectively. These foreign currency forward and option contracts, primarily euro based, have been designated as cash flow hedges, and accordingly, the effective portions of the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to earnings in the same periods during which the hedged transactions affect earnings.

To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term notes denominated in foreign currencies, we entered into cross-currency swap contracts. Under the terms of these contracts, we paid euros/pounds sterling and received U.S. dollars for the notional amounts at the inception of the contracts, and we exchange interest payments based on these notional amounts at fixed rates over the lives of the contracts in which we pay U.S. dollars and receive euros/pounds sterling. In addition, we will pay U.S. dollars to and receive euros/pounds sterling from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged notes, effectively converting the interest payments and principal repayment on these notes from euros/pounds sterling to U.S. dollars. These cross-currency swap contracts have been designated as cash flow hedges, and accordingly, the effective portions of the unrealized gains and losses on these contracts are reported in AOCI and reclassified to earnings in the same periods during which the hedged debt affects earnings. The notional amounts and interest rates of our cross-currency swaps are as follows (notional amounts in millions):



	Foreign currency				U.S. dollars
Hedged notes	Notional amount		Interest rate		Notional amount		Interest rate
2.125% 2019 euro Notes	€	675	2.125	%	$	864	2.6	%
5.50% 2026 pound sterling Notes	£	475	5.50	%	$	748	5.8	%
4.00% 2029 pound sterling Notes	£	700	4.00	%	$	1,122	4.3	%

The effective portions of the unrealized gain/(loss) recognized in other comprehensive income for our derivative instruments designated as cash flow hedges were as follows (in millions):



	Three months ended					Six months ended
	June 30,					June 30,
Derivatives in cash flow hedging relationships	2014			2013		2014		2013
Foreign currency contracts	$	(13	)	$	21	$	—	$	121
Cross-currency swap contracts	21			32		25		(93		)
Total	$	8		$	53	$	25	$	28

The locations in the Condensed Consolidated Statements of Income and the effective portions of the gain/(loss) reclassified out of AOCI into earnings for our derivative instruments designated as cash flow hedges were as follows (in millions):



		Three months ended					Six months ended
		June 30,					June 30,
Derivatives in cash flow hedging relationships	Statements of Income location	2014		2013			2014		2013
Foreign currency contracts	Product sales	$	—	$	7		$	—	$	3
Cross-currency swap contracts	Interest and other income, net	48		12			62		(128		)
Forward interest rate contracts	Interest expense, net	—		(1		)	—		(1		)
Total		$	48	$	18		$	62	$	(126	)

No portions of our cash flow hedge contracts are excluded from the assessment of hedge effectiveness, and the gains and losses of the ineffective portions of these hedging instruments were not material for the three and six months ended June 30, 2014 and 2013. As of June 30, 2014, the amounts expected to be reclassified out of AOCI into earnings over the next 12 months are approximately $36 million of net losses on our foreign currency and cross-currency swap contracts and approximately $1 million of losses on forward interest rate contracts.

Fair value hedges

To achieve a desired mix of fixed and floating interest rates on our long-term debt, we entered into interest rate swap contracts, which qualified and are designated as fair value hedges. The terms of these interest rate swap contracts correspond to the related hedged debt instruments and effectively converted a fixed interest rate coupon to a floating LIBOR-based coupon over the lives of the respective notes. During the year ended December 31, 2013, we entered into interest rate swap contracts with an aggregate notional amount of $4.4 billion with respect to our 3.45% 2020 Notes, 4.10% 2021 Notes, 3.875% 2021 Notes and 3.625% 2022 Notes. The contracts have rates that range from three-month LIBOR plus 1.1% to three-month LIBOR plus 2.0%. During the three months ended June 30, 2014, we entered into interest rate swap contracts with an aggregate notional amount of $2.25 billion with respect to our 1.25% 2017 Notes and our 2.20% 2019 Notes. The contracts have rates that range from three-month LIBOR plus 0.4% to three-month LIBOR plus 0.6%.

For derivative instruments that are designated and qualify as fair value hedges, the unrealized gain or loss on the derivative resulting from the change in fair value during the period as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk is recognized in current earnings. For the three and six months ended June 30, 2014, we included the unrealized losses on the hedged debt of $63 million and $125 million, respectively, in the same line item, Interest expense, net, in the Condensed Consolidated Statements of Income, as the offsetting unrealized gains of $63 million and $125 million, respectively, on the related interest rate swap agreements. For the three and six months ended June 30, 2013, we included the unrealized gains on the hedged debt of $113 million and $91 million, respectively, in the same line item, Interest expense, net, in the Condensed Consolidated Statements of Income, as the offsetting unrealized losses of $113 million and $91 million, respectively, on the related interest rate swap agreements.

Derivatives not designated as hedges

We enter into foreign currency forward contracts that are not designated as hedging transactions to reduce our exposure to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies. These exposures are hedged on a month-to-month basis. As of June 30, 2014, and December 31, 2013, the total notional amounts of these foreign currency forward contracts were $878 million and $999 million, respectively.

The location in the Condensed Consolidated Statements of Income and the amount of gain/(loss) recognized in earnings for our derivative instruments not designated as hedging instruments were as follows (in millions):



		Three months ended					Six months ended
		June 30,					June 30,
Derivatives not designated as hedging instruments	Statements of Income location	2014			2013		2014			2013
Foreign currency contracts	Interest and other income, net	$	(14	)	$	11	$	(12	)	$	(5	)

The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):



	Derivative assets			Derivative liabilities
June 30, 2014	Balance Sheet location	Fair value		Balance Sheet location	Fair value
Derivatives designated as hedging instruments:
Cross-currency swap contracts	Other current assets/ Other noncurrent assets	$	214	Accrued liabilities/ Other noncurrent liabilities	$	1
Foreign currency contracts	Other current assets/ Other noncurrent assets	31		Accrued liabilities/ Other noncurrent liabilities	82
Interest rate swap contracts	Other current assets/ Other noncurrent assets	30		Accrued liabilities/ Other noncurrent liabilities	66
Total derivatives designated as hedging instruments		275			149
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	1		Accrued liabilities	1
Total derivatives not designated as hedging instruments		1			1
Total derivatives		$	276		$	150



	Derivative assets			Derivative liabilities
December 31, 2013	Balance Sheet location	Fair value		Balance Sheet location	Fair value
Derivatives designated as hedging instruments:
Cross-currency swap contracts	Other current assets/ Other noncurrent assets	$	193	Accrued liabilities/ Other noncurrent liabilities	$	4
Foreign currency contracts	Other current assets/ Other noncurrent assets	53		Accrued liabilities/ Other noncurrent liabilities	104
Interest rate swap contracts	Other current assets/ Other noncurrent assets	—		Accrued liabilities/ Other noncurrent liabilities	161
Total derivatives designated as hedging instruments		246			269
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	—		Accrued liabilities	3
Total derivatives not designated as hedging instruments		—			3
Total derivatives		$	246		$	272

Our derivative contracts that were in liability positions as of June 30, 2014, contain certain credit-risk-related contingent provisions that would be triggered if: (i) we were to undergo a change in control and (ii) our or the surviving entity’s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change in control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due to or from a counterparty under these contracts may only be offset against other amounts due to or from the same counterparty if an event of default or termination, as defined, were to occur.

The cash flow effects of our derivatives contracts for the six months ended June 30, 2014 and 2013, are included within Net cash provided by operating activities in the Condensed Consolidated Statements of Cash Flows.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Contingencies and commitments	6 Months Ended
Contingencies and commitments	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Contingencies and commitments	Contingencies and commitments Contingencies In the ordinary course of business, we are involved in various legal proceedings and other matters—including those discussed in this Note—that are complex in nature and have outcomes that are difficult to predict. See Note 18, Contingencies and commitments to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2013, and Note 12, Contingencies and commitments to our condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2014, for further discussion of certain of our legal proceedings and other matters. We record accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Our legal proceedings range from cases brought by a single plaintiff to class actions with thousands of putative class members. These legal proceedings, as well as other matters, involve various aspects of our business and a variety of claims—including but not limited to patent infringement, marketing, pricing and trade practices and securities law—some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing, in Note 18, Contingencies and commitments to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2013, or in Note 12, Contingencies and commitments to our condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2014, plaintiffs seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort faced by us often extend for several years. As a result, none of the matters described in this filing have progressed sufficiently through discovery and/or development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these items, an adverse determination in one or more of these items currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below: Federal Securities Litigation — In re Amgen Inc. Securities Litigation On May 5, 2014, plaintiffs filed an unsealed, redacted version of their second consolidated amended complaint in this securities class action lawsuit. On May 13, 2014, Amgen and the other named defendants filed a motion to dismiss that complaint. On August 4, 2014, the court issued an order granting Amgen's and the other defendants’ motion to dismiss with respect to certain of the misrepresentations alleged in the complaint and otherwise denying the motion to dismiss. Following the court’s order, the complaint continues to allege that Amgen and certain of its officers and directors (the Federal Defendants) made false statements that resulted in: (i) deceiving the investing public regarding Amgen's prospects and business; (ii) artificially inflating the prices of Amgen's publicly traded securities; and (iii) causing plaintiff and other members of the class to purchase Amgen publicly traded securities at inflated prices. The complaint also continues to make off-label marketing allegations that, throughout the class period, the Federal Defendants improperly marketed Aranesp^® (darbepoetin alfa) and EPOGEN^® (epoetin alfa) for off-label uses while aware that there were alleged safety signals with these products. The named defendants have not changed and the alleged class period remains the same. ERISA Litigation On June 30, 2014, the U.S. Supreme Court granted the petition for certiorari filed by Amgen and the other named defendants, vacated the judgment of the U.S. Court of Appeals for the Ninth Circuit (the Ninth Circuit Court) and remanded this Employee Retirement Income Security Act (ERISA) class action case to the Ninth Circuit Court for reconsideration in light of the U.S. Supreme Court’s decision in Fifth Third Bancorp v. Dudenhoeffer, decided June 25, 2014.

Subsequent event	6 Months Ended
Subsequent event	Jun. 30, 2014
Subsequent Events [Abstract]
Subsequent event	Subsequent event On July 29, 2014, we announced a restructuring plan to invest in continuing innovation and the launch of our new pipeline molecules, while improving our cost structure. As part of the plan, we will reduce our staff by 2,400 to 2,900 by the end of 2015 and close our facilities in Washington state and Colorado. We will also reduce the number of buildings at our headquarters in Thousand Oaks, California. This is the first phase of our restructuring efforts, and we are evaluating additional efficiency initiatives, particularly in the area of shared services and other external expense categories to support our growth objectives. We expect to incur pre-tax accounting charges in the range of $775 million to $950 million, primarily in 2014 and 2015. The charges are comprised of accelerated depreciation and asset impairment of between approximately $400 million to $500 million, and the staff reductions will result in an estimated $375 million to $450 million of charges. Approximately 40% of the total charges will result in cash outlays, primarily associated with staff separation costs.

Summary of significant accounting policies (Policies)	6 Months Ended
Summary of significant accounting policies (Policies)	Jun. 30, 2014
Accounting Policies [Abstract]
Business	Business Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics.
Basis of presentation	Basis of presentation The financial information for the three and six months ended June 30, 2014 and 2013, is unaudited but includes all adjustments (consisting of only normal recurring adjustments, unless otherwise indicated), which Amgen considers necessary for a fair presentation of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2013 and in our Quarterly Report on Form 10-Q for the period ended March 31, 2014.
Principles of consolidation	Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. We do not have any significant interests in any variable interest entities. All material intercompany transactions and balances have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $7.2 billion and $6.9 billion as of June 30, 2014, and December 31, 2013, respectively.
Restricted investments	Restricted investments As of December, 31, 2013, we had restricted investments on our Condensed Consolidated Balance Sheet that were owned by ATL Holdings Limited (ATL Holdings), a wholly-owned subsidiary. ATL Holdings was an entity distinct from the Company and its other subsidiaries, with separate assets and liabilities. Because certain third parties owned Class A preferred shares of ATL Holdings, this entity was required to hold restricted investments, which were composed of interest-bearing securities, cash and related interest receivable as of December 31, 2013. On May 22, 2014, the Company repurchased all of the outstanding Class A preferred shares, and therefore, there were no remaining restricted investments on our Condensed Consolidated Balance Sheet as of June 30, 2014. See Note 8, Financing arrangements.
Recent accounting pronouncements	Recent accounting pronouncements In May 2014, a new accounting standard was issued that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. This new standard will be effective for interim and annual periods beginning January 1, 2017, and is required to be adopted retrospectively. We are currently evaluating the impact this new standard will have on our financial statements.

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References + Details

Business combinations (Tables)

6 Months Ended

Jun. 30, 2014

Onyx Pharmaceuticals, Inc. [Member]

Business Acquisition [Line Items]

Aggregate acquisition date consideration to acquire an entity

The aggregate consideration to acquire Onyx was paid in cash and consisted of (in millions):



Total consideration transferred	$	9,517
Compensation expense	197
Total cash paid	$	9,714

Schedule of recognized identified assets acquired and liabilities assumed

The consideration to acquire Onyx was allocated preliminarily to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):



Cash and cash equivalents	$	319
Marketable securities	337
Inventories	170
Indefinite-lived intangible assets - In-process research and development (IPR&D)	1,180
Finite-lived intangible assets - Developed product technology rights	6,190
Finite-lived intangible assets - Licensing rights	2,792
Goodwill	2,388
Convertible debt	(742		)
Assumed contingent consideration	(261		)
Deferred income taxes, net	(2,996		)
Other assets (liabilities), net	140
Total consideration	$	9,517

Product Rights [Member]

Business Acquisition [Line Items]

Aggregate acquisition date consideration to acquire an entity

The aggregate consideration transferred consisted of (in millions):



Total consideration transferred or to be transferred	$	497
Settlement of preexisting relationship at fair value	(99		)
Total consideration transferred to acquire the Product Rights	$	398

Schedule of recognized identified assets acquired and liabilities assumed

The consideration to acquire the Product Rights was allocated to the acquisition date fair values of assets acquired as follows (in millions):



Finite-lived intangible assets - Marketing-related rights	$	363
Finite-lived intangible assets - Developed product technology rights	11
Goodwill	3
Other assets	21
Total consideration	$	398

Earnings per share (Tables)

6 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Computation for basic and diluted earnings per share

The computation for basic and diluted EPS was as follows (in millions, except per share data):



	Three months ended				Six months ended
	June 30,				June 30,
	2014		2013		2014		2013
Income (Numerator):
Net income for basic and diluted EPS	$	1,547	$	1,258	$	2,620	$	2,692

Shares (Denominator):
Weighted-average shares for basic EPS	759		752		758		752
Effect of dilutive securities	9		12		10		12
Weighted-average shares for diluted EPS	768		764		768		764

Basic EPS	$	2.04	$	1.67	$	3.46	$	3.58
Diluted EPS	$	2.01	$	1.65	$	3.41	$	3.52

Available-for-sale investments (Tables)

6 Months Ended

Jun. 30, 2014

Investments, Debt and Equity Securities [Abstract]

Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security

The amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security were as follows (in millions):



Type of security as of June 30, 2014	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value
U.S. Treasury securities	$	2,886	$	5	$	(2	)	$	2,889
Other government-related debt securities:
U.S.	963		1		(3		)	961
Foreign and other	1,547		26		(9		)	1,564
Corporate debt securities:
Financial	5,131		35		(3		)	5,163
Industrial	5,337		46		(10		)	5,373
Other	570		5		(1		)	574
Residential mortgage-backed securities	1,746		5		(11		)	1,740
Other mortgage- and asset-backed securities	1,926		1		(53		)	1,874
Money market mutual funds	3,328		—		—			3,328
Other short-term interest-bearing securities	2,138		—		—			2,138
Total interest-bearing securities	25,572		124		(92		)	25,604
Equity securities	86		—		(4		)	82
Total available-for-sale investments	$	25,658	$	124	$	(96	)	$	25,686



Type of security as of December 31, 2013	Amortized cost		Gross unrealized gains		Gross unrealized losses			Estimated fair value
U.S. Treasury securities	$	4,737	$	2	$	(9	)	$	4,730
Other government-related debt securities:
U.S.	1,087		—		(8		)	1,079
Foreign and other	1,574		13		(41		)	1,546
Corporate debt securities:
Financial	3,667		28		(19		)	3,676
Industrial	3,745		36		(21		)	3,760
Other	388		4		(2		)	390
Residential mortgage-backed securities	1,478		3		(21		)	1,460
Other mortgage- and asset-backed securities	1,555		1		(45		)	1,511
Money market mutual funds	3,366		—		—			3,366
Other short-term interest-bearing securities	750		—		—			750
Total interest-bearing securities	22,347		87		(166		)	22,268
Equity securities	85		10		—			95
Total available-for-sale investments	$	22,432	$	97	$	(166	)	$	22,363

Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets

The fair values of available-for-sale investments by classification in the Condensed Consolidated Balance Sheets were as follows (in millions):



Classification in the Condensed Consolidated Balance Sheets	June 30, 2014		December 31, 2013
Cash and cash equivalents	$	3,768	$	3,266
Marketable securities	21,836		15,596
Other assets — noncurrent	82		95
Restricted investments	—		3,406
Total available-for-sale investments	$	25,686	$	22,363

Fair values of available-for-sale interest-bearing security investments by contractual maturity



Contractual maturity	June 30, 2014		December 31, 2013
Maturing in one year or less	$	5,820	$	6,799
Maturing after one year through three years	5,927		4,785
Maturing after three years through five years	7,394		6,057
Maturing after five years through ten years	2,671		1,656
Maturing after ten years	178		—
Mortgage- and asset-backed securities	3,614		2,971
Total interest-bearing securities	$	25,604	$	22,268

Available-for-sale securities, fair value and unrealized losses

The unrealized losses on available-for-sale investments and their related fair values were as follows (in millions):



	Less than 12 months					12 months or greater
Type of security as of June 30, 2014	Fair value		Unrealized losses			Fair value		Unrealized losses
U.S. Treasury securities	$	700	$	(1	)	$	280	$	(1	)
Other government-related debt securities:
U.S.	—		—			323		(3		)
Foreign and other	148		(2		)	277		(7		)
Corporate debt securities:
Financial	1,047		(2		)	134		(1		)
Industrial	1,831		(9		)	130		(1		)
Other	126		(1		)	—		—
Residential mortgage-backed securities	459		(3		)	462		(8		)
Other mortgage- and asset-backed securities	514		(5		)	860		(48		)
Equity securities	16		(4		)	—		—
Total	$	4,841	$	(27	)	$	2,466	$	(69	)



	Less than 12 months					12 months or greater
Type of security as of December 31, 2013	Fair value		Unrealized losses			Fair value		Unrealized losses
U.S. Treasury securities	$	2,362	$	(9	)	$	—	$	—
Other government-related debt securities:
U.S.	789		(8		)	—		—
Foreign and other	986		(38		)	39		(3		)
Corporate debt securities:
Financial	1,781		(19		)	—		—
Industrial	1,543		(21		)	1		—
Other	182		(2		)	—		—
Residential mortgage-backed securities	794		(14		)	257		(7		)
Other mortgage- and asset-backed securities	982		(29		)	313		(16		)
Total	$	9,419	$	(140	)	$	610	$	(26	)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Inventories (Tables)

6 Months Ended

Jun. 30, 2014

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following (in millions):



	June 30, 2014		December 31, 2013
Raw materials	$	202	$	217
Work in process	1,836		2,064
Finished goods	916		738
Total inventories	$	2,954	$	3,019

Goodwill and other intangible assets (Tables)

6 Months Ended

Jun. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of goodwill

The changes in the carrying amounts of goodwill were as follows (in millions):



	Six months ended June 30,
	2014			2013
Beginning balance	$	14,968		$	12,662
Goodwill related to acquisitions of businesses⁽¹⁾	(128		)	(46		)
Currency translation adjustments	4			(38		)
Ending balance	$	14,844		$	12,578


⁽¹⁾	Composed primarily of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in business combinations recorded during their respective measurement periods.

Schedule of identifiable intangible assets

Identifiable intangible assets consisted of the following (in millions):



	June 30, 2014							December 31, 2013
	Gross carrying amount		Accumulated amortization			Intangible assets, net		Gross carrying amount		Accumulated amortization			Intangible assets, net
Finite-lived intangible assets:
Developed product technology rights	$	10,421	$	(3,753	)	$	6,668	$	10,130	$	(3,347	)	$	6,783
Licensing rights	3,241		(543		)	2,698		3,241		(366		)	2,875
R&D technology rights	1,206		(538		)	668		1,207		(496		)	711
Marketing-related rights	1,251		(439		)	812		619		(366		)	253
Total finite-lived intangible assets	16,119		(5,273		)	10,846		15,197		(4,575		)	10,622
Indefinite-lived intangible assets:
IPR&D	2,653		—			2,653		2,640		—			2,640
Total identifiable intangible assets	$	18,772	$	(5,273	)	$	13,499	$	17,837	$	(4,575	)	$	13,262

Financing arrangements (Tables)

6 Months Ended

Jun. 30, 2014

Debt Disclosure [Abstract]

Carrying values and the fixed contractual coupon rates of long-term borrowings

The carrying values and the fixed contractual coupon rates, as applicable, of our long-term borrowings were as follows (in millions):



	June 30, 2014			December 31, 2013
1.875% notes due 2014 (1.875% 2014 Notes)	$	1,000		$	1,000
4.85% notes due 2014 (4.85% 2014 Notes)	1,000			1,000
2.30% notes due 2016 (2.30% 2016 Notes)	749			749
2.50% notes due 2016 (2.50% 2016 Notes)	1,000			999
Floating Rate Notes due 2017	600			—
1.25% notes due 2017 (1.25% 2017 Notes)	849			—
2.125% notes due 2017 (2.125% 2017 Notes)	1,249			1,248
5.85% notes due 2017 (5.85% 2017 Notes)	1,099			1,099
6.15% notes due 2018 (6.15% 2018 Notes)	500			500
Master Repurchase Agreement obligation due 2018	—			3,100
Term Loan due 2018	4,625			4,875
4.375% euro-denominated notes due 2018 (4.375% 2018 euro Notes)	748			751
Floating Rate Notes due 2019	250			—
2.20% notes due 2019 (2.20% 2019 Notes)	1,397			—
5.70% notes due 2019 (5.70% 2019 Notes)	999			999
2.125% euro-denominated notes due 2019 (2.125% 2019 euro Notes)	922			925
4.50% notes due 2020 (4.50% 2020 Notes)	300			300
3.45% notes due 2020 (3.45% 2020 Notes)	898			898
4.10% notes due 2021 (4.10% 2021 Notes)	998			998
3.875% notes due 2021 (3.875% 2021 Notes)	1,746			1,746
3.625% notes due 2022 (3.625% 2022 Notes)	747			747
3.625% notes due 2024 (3.625% 2024 Notes)	1,398			—
5.50% pound-sterling-denominated notes due 2026 (5.50% 2026 pound sterling Notes)	807			781
4.00% pound-sterling-denominated notes due 2029 (4.00% 2029 pound sterling Notes)	1,183			1,144
6.375% notes due 2037 (6.375% 2037 Notes)	899			899
6.90% notes due 2038 (6.90% 2038 Notes)	499			499
6.40% notes due 2039 (6.40% 2039 Notes)	996			996
5.75% notes due 2040 (5.75% 2040 Notes)	697			697
4.95% notes due 2041 (4.95% 2041 Notes)	596			596
5.15% notes due 2041 (5.15% 2041 Notes)	2,233			2,233
5.65% notes due 2042 (5.65% 2042 Notes)	1,244			1,244
5.375% notes due 2043 (5.375% 2043 Notes)	1,000			1,000
Other notes	100			105
Total debt	33,328			32,128
Less current portion	(2,500		)	(2,505		)
Total noncurrent debt	$	30,828		$	29,623

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Stockholders' equity (Tables)

6 Months Ended

Jun. 30, 2014

Equity [Abstract]

Components of Accumulated Other Comprehensive Income

The components of accumulated other comprehensive income (AOCI) were as follows (in millions):



	Foreign currency translation			Cash flow hedges			Available-for-sale securities			Other			AOCI
Balance as of December 31, 2013	$	(68	)	$	(33	)	$	(43	)	$	(17	)	$	(161	)
Foreign currency translation adjustments	(12		)	—			—			—			(12		)
Unrealized gains	—			17			66			1			84
Reclassification adjustments to income	—			(14		)	(2		)	—			(16		)
Income taxes	4			(1		)	(24		)	—			(21		)
Balance as of March 31, 2014	$	(76	)	$	(31	)	$	(3	)	$	(16	)	$	(126	)
Foreign currency translation adjustments	9			—			—			—			9
Unrealized gains	—			8			73			—			81
Reclassification adjustments to income	—			(48		)	(40		)	—			(88		)
Income taxes	(2		)	15			(12		)	—			1
Balance as of June 30, 2014	$	(69	)	$	(56	)	$	18		$	(16	)	$	(123	)

Reclassifications out of Accumulated Other Comprehensive Income

The reclassifications out of AOCI to Net income were as follows (in millions):



	Amounts reclassified out of AOCI
Components of AOCI	Three months ended June 30, 2014			Three months ended June 30, 2013			Line item affected in the Statements of Income
Cash flow hedges:
Foreign currency contract gains	$	—		$	7		Product sales
Cross-currency swap contract gains	48			12			Interest and other income, net
Forward interest rate contract losses	—			(1		)	Interest expense, net
	48			18			Total before income tax
	(18		)	(7		)	Tax expense
	$	30		$	11		Net of taxes
Available-for-sale securities:
Net realized gains	$	40		$	7		Interest and other income, net
	(15		)	(3		)	Tax expense
	$	25		$	4		Net of taxes



	Amounts reclassified out of AOCI
Components of AOCI	Six months ended June 30, 2014			Six months ended June 30, 2013			Line item affected in the Statements of Income
Cash flow hedges:
Foreign currency contract gains	$	—		$	3		Product sales
Cross-currency swap contract gains (losses)	62			(128		)	Interest and other income, net
Forward interest rate contract losses	—			(1		)	Interest expense, net
	62			(126		)	Total before income tax
	(23		)	46			Tax (expense)/benefit
	$	39		$	(80	)	Net of taxes
Available-for-sale securities:
Net realized gains	$	42		$	74		Interest and other income, net
	(16		)	(28		)	Tax expense
	$	26		$	46		Net of taxes

Fair value measurement (Tables)

6 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair value of each major class of financial assets and liabilities measured at fair value on a recurring basis

The fair value of each major class of the Company’s financial assets and liabilities measured at fair value on a recurring basis was as follows (in millions):



	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Fair value measurement
as of June 30, 2014, using:							Total
Assets:
Available-for-sale investments:
U.S. Treasury securities	$	2,889	$	—	$	—	$	2,889
Other government-related debt securities:
U.S.	—		961		—		961
Foreign and other	—		1,564		—		1,564
Corporate debt securities:
Financial	—		5,163		—		5,163
Industrial	—		5,373		—		5,373
Other	—		574		—		574
Residential mortgage-backed securities	—		1,740		—		1,740
Other mortgage- and asset-backed securities	—		1,874		—		1,874
Money market mutual funds	3,328		—		—		3,328
Other short-term interest-bearing securities	—		2,138		—		2,138
Equity securities	82		—		—		82
Derivatives:
Foreign currency contracts	—		32		—		32
Cross-currency swap contracts	—		214		—		214
Interest rate swap contracts	—		30		—		30
Total assets	$	6,299	$	19,663	$	—	$	25,962

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	83	$	—	$	83
Cross-currency swap contracts	—		1		—		1
Interest rate swap contracts	—		66		—		66
Contingent consideration obligations in connection with business combinations	—		—		610		610
Total liabilities	$	—	$	150	$	610	$	760



	Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Fair value measurement
as of December 31, 2013, using:							Total
Assets:
Available-for-sale investments:
U.S. Treasury securities	$	4,730	$	—	$	—	$	4,730
Other government-related debt securities:
U.S.	—		1,079		—		1,079
Foreign and other	—		1,546		—		1,546
Corporate debt securities:
Financial	—		3,676		—		3,676
Industrial	—		3,760		—		3,760
Other	—		390		—		390
Residential mortgage-backed securities	—		1,460		—		1,460
Other mortgage- and asset-backed securities	—		1,511		—		1,511
Money market mutual funds	3,366		—		—		3,366
Other short-term interest-bearing securities	—		750		—		750
Equity securities	95		—		—		95
Derivatives:
Foreign currency contracts	—		53		—		53
Cross-currency swap contracts	—		193		—		193
Total assets	$	8,191	$	14,418	$	—	$	22,609

Liabilities:
Derivatives:
Foreign currency contracts	$	—	$	107	$	—	$	107
Cross-currency swap contracts	—		4		—		4
Interest rate swap contracts	—		161		—		161
Contingent consideration obligations in connection with business combinations	—		—		595		595
Total liabilities	$	—	$	272	$	595	$	867

Changes in carrying amounts of contingent consideration obligations

The changes in carrying amounts of contingent consideration obligations were as follows (in millions):



	Three months ended June 30,				Six months ended June 30,
	2014		2013		2014		2013
Beginning balance	$	596	$	222	$	595	$	221
Net changes in valuation	14		110		15		111
Ending balance	$	610	$	332	$	610	$	332

Derivative instruments (Tables)

6 Months Ended

Jun. 30, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of notional amounts and interest rates for cross-currency swaps

The notional amounts and interest rates of our cross-currency swaps are as follows (notional amounts in millions):



	Foreign currency				U.S. dollars
Hedged notes	Notional amount		Interest rate		Notional amount		Interest rate
2.125% 2019 euro Notes	€	675	2.125	%	$	864	2.6	%
5.50% 2026 pound sterling Notes	£	475	5.50	%	$	748	5.8	%
4.00% 2029 pound sterling Notes	£	700	4.00	%	$	1,122	4.3	%

Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges

The effective portions of the unrealized gain/(loss) recognized in other comprehensive income for our derivative instruments designated as cash flow hedges were as follows (in millions):



	Three months ended					Six months ended
	June 30,					June 30,
Derivatives in cash flow hedging relationships	2014			2013		2014		2013
Foreign currency contracts	$	(13	)	$	21	$	—	$	121
Cross-currency swap contracts	21			32		25		(93		)
Total	$	8		$	53	$	25	$	28

Location in the Condensed Consolidated Statements of Income and the effective portion of gain (loss) reclassified from Accumulated Other Comprehensive Income into earnings for our derivative instruments designated as cash flow hedges



		Three months ended					Six months ended
		June 30,					June 30,
Derivatives in cash flow hedging relationships	Statements of Income location	2014		2013			2014		2013
Foreign currency contracts	Product sales	$	—	$	7		$	—	$	3
Cross-currency swap contracts	Interest and other income, net	48		12			62		(128		)
Forward interest rate contracts	Interest expense, net	—		(1		)	—		(1		)
Total		$	48	$	18		$	62	$	(126	)

Location in the Condensed Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for the derivative instruments not designated as hedging instruments



		Three months ended					Six months ended
		June 30,					June 30,
Derivatives not designated as hedging instruments	Statements of Income location	2014			2013		2014			2013
Foreign currency contracts	Interest and other income, net	$	(14	)	$	11	$	(12	)	$	(5	)

Fair values of derivatives included in the Condensed Consolidated Balance Sheets

The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):



	Derivative assets			Derivative liabilities
June 30, 2014	Balance Sheet location	Fair value		Balance Sheet location	Fair value
Derivatives designated as hedging instruments:
Cross-currency swap contracts	Other current assets/ Other noncurrent assets	$	214	Accrued liabilities/ Other noncurrent liabilities	$	1
Foreign currency contracts	Other current assets/ Other noncurrent assets	31		Accrued liabilities/ Other noncurrent liabilities	82
Interest rate swap contracts	Other current assets/ Other noncurrent assets	30		Accrued liabilities/ Other noncurrent liabilities	66
Total derivatives designated as hedging instruments		275			149
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	1		Accrued liabilities	1
Total derivatives not designated as hedging instruments		1			1
Total derivatives		$	276		$	150



	Derivative assets			Derivative liabilities
December 31, 2013	Balance Sheet location	Fair value		Balance Sheet location	Fair value
Derivatives designated as hedging instruments:
Cross-currency swap contracts	Other current assets/ Other noncurrent assets	$	193	Accrued liabilities/ Other noncurrent liabilities	$	4
Foreign currency contracts	Other current assets/ Other noncurrent assets	53		Accrued liabilities/ Other noncurrent liabilities	104
Interest rate swap contracts	Other current assets/ Other noncurrent assets	—		Accrued liabilities/ Other noncurrent liabilities	161
Total derivatives designated as hedging instruments		246			269
Derivatives not designated as hedging instruments:
Foreign currency contracts	Other current assets	—		Accrued liabilities	3
Total derivatives not designated as hedging instruments		—			3
Total derivatives		$	246		$	272

Summary of significant accounting policies (Details) - USD ($) $ in Billions	Jun. 30, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Accumulated depreciation and amortization on property, plant and equipment	$ 7.2	$ 6.9

Business combinations (Details) - Onyx Pharmaceuticals, Inc. [Member] - USD ($) $ in Millions		1 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Business Acquisition [Line Items]
Total consideration transferred	$ 9,517	$ 9,517
Compensation expense	197
Total cash paid	$ 9,714

Business combinations (Details 1) - USD ($) $ in Millions	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Goodwill	$ 14,844	$ 14,968	$ 12,578	$ 12,662
Onyx Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	319
Marketable securities	337
Inventories	170
Indefinite-lived intangible assets - In-process research and development (IPR&D)	1,180
Goodwill	2,388
Convertible debt	(742)
Assumed contingent consideration	(261)
Deferred income taxes, net	(2,996)
Other assets (liabilities), net	140
Total consideration	9,517
Product Rights [Member]
Business Acquisition [Line Items]
Goodwill		3
Other assets		21
Total consideration		398
Marketing-Related Rights [Member] \| Product Rights [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets		363
Developed Product Technology Rights [Member] \| Onyx Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets	6,190
Developed Product Technology Rights [Member] \| Product Rights [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets		$ 11
Licensing Rights [Member] \| Onyx Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets	$ 2,792

Business combinations (Details 2) - Product Rights [Member] $ in Millions	1 Months Ended
	Dec. 31, 2013 USD ($)
Business Acquisition [Line Items]
Total consideration transferred or to be transferred	$ 497
Settlement of preexisting relationship at fair value	(99)
Total consideration transferred to acquire the Product Rights	$ 398

Business combinations (Details Textual)
$ in Millions

1 Months Ended

3 Months Ended

6 Months Ended

Sep. 30, 2013

USD ($)

Dec. 31, 2013

USD ($)

market

Sep. 30, 2013

USD ($)

Dec. 31, 2013

USD ($)

Jun. 30, 2014

USD ($)

oncology_assets

Jun. 30, 2013

USD ($)

Business Acquisition [Line Items]

Reduction in goodwill

^[1]

$ 128

$ 46

Onyx Pharmaceuticals, Inc. [Member]

Business Acquisition [Line Items]

Number of partnered oncology assets | oncology_assets

Cash payments

$ 9,517

Reduction in goodwill

$ 138

Increase in deferred income taxes

Decrease in inventory

Onyx Pharmaceuticals, Inc. [Member] | Selling, General and Administrative Expenses [Member]

Business Acquisition [Line Items]

Share-based compensation expense

$ 197

Onyx Pharmaceuticals, Inc. [Member] | Developed Product Technology Rights [Member]

Business Acquisition [Line Items]

Increase in developed product technology rights

280

Finite-lived intangible assets, estimated useful life (in years)

12 years

Onyx Pharmaceuticals, Inc. [Member] | Licensing Rights [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets, estimated useful life (in years)

10 years

Onyx Pharmaceuticals, Inc. [Member] | Common Stockholders [Member]

Business Acquisition [Line Items]

Cash payments

$ 9,186

Onyx Pharmaceuticals, Inc. [Member] | Equity Award Holders for Services Rendered Prior to Date of Acquisition [Member]

Business Acquisition [Line Items]

Cash payments

$ 331

Product Rights [Member]

Business Acquisition [Line Items]

Number of markets holding acquired licenses | market

100

Total consideration transferred or to be transferred

$ 497

Fair value of contract terminated

$ 99

Product Rights [Member] | Cost of Sales [Member]

Business Acquisition [Line Items]

Fair value of contract terminated

$ 99

Product Rights [Member] | Developed Product Technology Rights [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets, estimated useful life (in years)

3 years 6 months

Product Rights [Member] | Marketing-Related Rights [Member]

Business Acquisition [Line Items]

Finite-lived intangible assets, estimated useful life (in years)

5 years

[1]	Composed primarily of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in business combinations recorded during their respective measurement periods.

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Income taxes (Details) - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income taxes (Textual) [Abstract]
Effective income tax rate	12.00%	10.50%	11.50%	2.00%
Effective tax rate for the period excluding the impact of the tax credits associated with the new Pr excise tax	16.70%	15.60%	16.20%	7.50%
Increase in gross amount of unrecognized tax benefits for period	$ 100		$ 165
Decrease in unrecognized tax benefits that is reasonably possible within the succeeding 12 months due to resolution of federal and state audits	$ 70		$ 70
Puerto Rico Excise Tax [Member]
Puerto Rico Excise Tax Rate [Line Items]
Effective excise tax rate for first half of 2013			2.75%
Excise tax rate effective July 1, 2013 through 2017			4.00%

Earnings per share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income (Numerator):
Net income for basic and diluted EPS	$ 1,547	$ 1,258	$ 2,620	$ 2,692
Shares (Denominator):
Weighted-average shares for basic EPS	759	752	758	752
Effect of dilutive securities	9	12	10	12
Weighted-average shares for diluted EPS	768	764	768	764
Basic EPS (in usd per share)	$ 2.04	$ 1.67	$ 3.46	$ 3.58
Diluted EPS (in usd per share)	$ 2.01	$ 1.65	$ 3.41	$ 3.52

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Available-for-sale investments (Details) - USD ($) $ in Millions	Jun. 30, 2014	Dec. 31, 2013
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	$ 25,658	$ 22,432
Gross unrealized gains	124	97
Gross unrealized losses	(96)	(166)
Total available-for-sale investments	25,686	22,363
U.S. Treasury securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	2,886	4,737
Gross unrealized gains	5	2
Gross unrealized losses	(2)	(9)
Total available-for-sale investments	2,889	4,730
Other government-related debt securities - U.S. [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	963	1,087
Gross unrealized gains	1	0
Gross unrealized losses	(3)	(8)
Total available-for-sale investments	961	1,079
Other government-related debt securities - Foreign and other [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	1,547	1,574
Gross unrealized gains	26	13
Gross unrealized losses	(9)	(41)
Total available-for-sale investments	1,564	1,546
Corporate debt securities - Financial [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	5,131	3,667
Gross unrealized gains	35	28
Gross unrealized losses	(3)	(19)
Total available-for-sale investments	5,163	3,676
Corporate debt securities - Industrial [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	5,337	3,745
Gross unrealized gains	46	36
Gross unrealized losses	(10)	(21)
Total available-for-sale investments	5,373	3,760
Corporate debt securities - Other [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	570	388
Gross unrealized gains	5	4
Gross unrealized losses	(1)	(2)
Total available-for-sale investments	574	390
Residential mortgage-backed securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	1,746	1,478
Gross unrealized gains	5	3
Gross unrealized losses	(11)	(21)
Total available-for-sale investments	1,740	1,460
Other mortgage- and asset-backed securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	1,926	1,555
Gross unrealized gains	1	1
Gross unrealized losses	(53)	(45)
Total available-for-sale investments	1,874	1,511
Money market mutual funds [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	3,328	3,366
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Total available-for-sale investments	3,328	3,366
Other short-term interest-bearing securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	2,138	750
Gross unrealized gains	0	0
Gross unrealized losses	0	0
Total available-for-sale investments	2,138	750
Total interest-bearing securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	25,572	22,347
Gross unrealized gains	124	87
Gross unrealized losses	(92)	(166)
Total available-for-sale investments	25,604	22,268
Equity securities [Member]
Amortized cost, gross unrealized gains, gross unrealized losses and estimated fair values of available-for-sale investments by type of security
Amortized cost	86	85
Gross unrealized gains	0	10
Gross unrealized losses	(4)	0
Total available-for-sale investments	$ 82	$ 95

Available-for-sale investments (Details 1) - USD ($) $ in Millions	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	$ 4,352	$ 3,805	$ 5,806	$ 3,257
Marketable securities	21,836	15,596
Other assets — noncurrent	1,492	1,767
Restricted investments	0	3,412
Total available-for-sale investments	25,686	22,363
Available-for-sale investments [Member]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Cash and cash equivalents	3,768	3,266
Other assets — noncurrent	82	95
Available-for-sale investments [Member] \| ATL Holdings [Member]
Fair values of available-for-sale investments by classification in the Consolidated Balance Sheets
Restricted investments	$ 0	$ 3,406

Available-for-sale investments (Details 2) - USD ($) $ in Millions	Jun. 30, 2014	Dec. 31, 2013
Fair values of available-for-sale debt security investments by contractual maturity
Maturing in one year or less	$ 5,820	$ 6,799
Maturing after one year through three years	5,927	4,785
Maturing after three years through five years	7,394	6,057
Maturing after five years through ten years	2,671	1,656
Maturing after ten years	178	0
Mortgage- and asset-backed securities	3,614	2,971
Total available-for-sale investments	25,686	22,363
Total interest-bearing securities [Member]
Fair values of available-for-sale debt security investments by contractual maturity
Total available-for-sale investments	$ 25,604	$ 22,268

Available-for-sale investments Available-for-sale investments (Details 3) - USD ($) $ in Millions	Jun. 30, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	$ 4,841	$ 9,419
Less than 12 months, Unrealized losses	(27)	(140)
12 months or greater, Fair value	2,466	610
12 months or greater, Unrealized losses	(69)	(26)
U.S. Treasury securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	700	2,362
Less than 12 months, Unrealized losses	(1)	(9)
12 months or greater, Fair value	280	0
12 months or greater, Unrealized losses	(1)	0
Other government-related debt securities - U.S. [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	0	789
Less than 12 months, Unrealized losses	0	(8)
12 months or greater, Fair value	323	0
12 months or greater, Unrealized losses	(3)	0
Other government-related debt securities - Foreign and other [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	148	986
Less than 12 months, Unrealized losses	(2)	(38)
12 months or greater, Fair value	277	39
12 months or greater, Unrealized losses	(7)	(3)
Corporate debt securities - Financial [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	1,047	1,781
Less than 12 months, Unrealized losses	(2)	(19)
12 months or greater, Fair value	134	0
12 months or greater, Unrealized losses	(1)	0
Corporate debt securities - Industrial [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	1,831	1,543
Less than 12 months, Unrealized losses	(9)	(21)
12 months or greater, Fair value	130	1
12 months or greater, Unrealized losses	(1)	0
Corporate debt securities - Other [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	126	182
Less than 12 months, Unrealized losses	(1)	(2)
12 months or greater, Fair value	0	0
12 months or greater, Unrealized losses	0	0
Residential mortgage-backed securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	459	794
Less than 12 months, Unrealized losses	(3)	(14)
12 months or greater, Fair value	462	257
12 months or greater, Unrealized losses	(8)	(7)
Other mortgage- and asset-backed securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	514	982
Less than 12 months, Unrealized losses	(5)	(29)
12 months or greater, Fair value	860	313
12 months or greater, Unrealized losses	(48)	$ (16)
Equity securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Less than 12 months, Fair value	16
Less than 12 months, Unrealized losses	(4)
12 months or greater, Fair value	0
12 months or greater, Unrealized losses	$ 0

Available-for-sale investments (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Available-for-sale investments (Textual) [Abstract]
Cash	$ 584		$ 584		$ 539
Total realized gains	57	$ 33	85	$ 118
Total realized losses	$ 17	$ 26	$ 43	$ 44
ATL Holdings [Member]
Investments [Line Items]
Interest receivable					$ 6

Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2014	Dec. 31, 2013
Inventories
Raw materials	$ 202	$ 217
Work in process	1,836	2,064
Finished goods	916	738
Total inventories	$ 2,954	$ 3,019

Goodwill and other intangible assets (Details) - USD ($)
$ in Millions

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Goodwill [Roll Forward]

Beginning balance

$ 14,968

$ 12,662

^[1]

(128)

(46)

Currency translation adjustments

(38)

Ending balance

$ 14,844

$ 12,578

[1]	Composed primarily of adjustments to goodwill resulting from changes to the acquisition date fair values of net assets acquired in business combinations recorded during their respective measurement periods.

Goodwill and other intangible assets (Details 1) - USD ($) $ in Millions	Jun. 30, 2014	Dec. 31, 2013
Finite-lived intangible assets:
Gross carrying amount	$ 16,119	$ 15,197
Accumulated amortization	(5,273)	(4,575)
Intangible assets, net	10,846	10,622
Indefinite-lived intangible assets:
Total gross carrying amount	18,772	17,837
Total accumulated amortization	(5,273)	(4,575)
Total intangible assets, net	13,499	13,262
IPR&D [Member]
Indefinite-lived intangible assets:
Indefinite-lived intangible assets	2,653	2,640
Developed Product Technology Rights [Member]
Finite-lived intangible assets:
Gross carrying amount	10,421	10,130
Accumulated amortization	(3,753)	(3,347)
Intangible assets, net	6,668	6,783
Licensing Rights [Member]
Finite-lived intangible assets:
Gross carrying amount	3,241	3,241
Accumulated amortization	(543)	(366)
Intangible assets, net	2,698	2,875
R&D Technology Rights [Member]
Finite-lived intangible assets:
Gross carrying amount	1,206	1,207
Accumulated amortization	(538)	(496)
Intangible assets, net	668	711
Marketing-related Rights [Member]
Finite-lived intangible assets:
Gross carrying amount	1,251	619
Accumulated amortization	(439)	(366)
Intangible assets, net	$ 812	$ 253

Goodwill and other intangible assets (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization charges associated with finite-lived intangible assets	$ 341	$ 119	$ 698	$ 236
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Total estimated amortization of finite- lived intangible assets for the six months ended 2014	670		670
Total estimated amortization of finite- lived intangible assets for 2015	1,300		1,300
Total estimated amortization of finite- lived intangible assets for 2016	1,300		1,300
Total estimated amortization of finite- lived intangible assets for 2017	1,200		1,200
Total estimated amortization of finite- lived intangible assets for 2018	999		999
Total estimated amortization of finite- lived intangible assets for 2019	926		926
Glaxo Group Limited [Member]
Finite-Lived Intangible Assets [Line Items]
Amount of payments to be made in exchange for the early termination of the Collaboration Agreement	$ 275		$ 275

Financing arrangements (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
Financing arrangements (Details) - USD ($) $ in Millions	May 31, 2014	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Carrying values of long-term borrowings
Other notes		$ 100		$ 105
Total debt		33,328		32,128
Less current portion		(2,500)		(2,505)
Total noncurrent debt		30,828		29,623
Repayment of debt		3,355	$ 2,500
Debt issuance	$ 4,500
Redemption price, percentage	101.00%
Interest Expense, Net [Member]
Carrying values of long-term borrowings
Debt issuance cost to be amortized	$ 18
1.875% notes due 2014 (1.875% 2014 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, current		$ 1,000		$ 1,000
Interest rate, stated percentage		1.875%		1.875%
4.85% notes due 2014 (4.85% 2014 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, current		$ 1,000		$ 1,000
Interest rate, stated percentage		4.85%		4.85%
2.30% notes due 2016 (2.30% 2016 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 749		$ 749
Interest rate, stated percentage		2.30%		2.30%
2.50% notes due 2016 (2.50% 2016 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 1,000		$ 999
Interest rate, stated percentage		2.50%		2.50%
Floating Rate Notes due 2017 [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 600		$ 0
Floating Rate Notes due 2017 [Member] \| LIBOR [Member]
Carrying values of long-term borrowings
Basis spread on variable rate	0.38%
1.25% notes due 2017 (1.25% 2017 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 849		0
Interest rate, stated percentage		1.25%
2.125% notes due 2017 (2.125% 2017 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 1,249		$ 1,248
Interest rate, stated percentage		2.125%		2.125%
5.85% notes due 2017 (5.85% 2017 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 1,099		$ 1,099
Interest rate, stated percentage		5.85%		5.85%
6.15% notes due 2018 (6.15% 2018 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 500		$ 500
Interest rate, stated percentage		6.15%		6.15%
Master Repurchase Agreement Obligation due 2018 [Member]
Carrying values of long-term borrowings
Loans payable to bank, noncurrent		$ 0		$ 3,100
Repayment of debt		3,100
Term Loan Due 2018 [Member]
Carrying values of long-term borrowings
Loans payable to bank		4,625		4,875
Term Loan Credit Facility, repayment of principal		250
Other notes [Member]
Carrying values of long-term borrowings
Repayment of debt		5
4.375% euro denominated notes due 2018 (4.375% 2018 euro Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 748		$ 751
Interest rate, stated percentage		4.375%		4.375%
Floating Rate Notes due 2019 [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 250		$ 0
Floating Rate Notes due 2019 [Member] \| LIBOR [Member]
Carrying values of long-term borrowings
Basis spread on variable rate	0.60%
2.20% notes due 2019 (2.20% 2019 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 1,397		0
Interest rate, stated percentage		2.20%
Debt instrument, redemption period	1 month
5.70% notes due 2019 (5.70% 2019 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 999		$ 999
Interest rate, stated percentage		5.70%		5.70%
2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 922		$ 925
Interest rate, stated percentage		2.125%		2.125%
4.50% notes due 2020 (4.50% 2020 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 300		$ 300
Interest rate, stated percentage		4.50%		4.50%
3.45% notes due 2020 (3.45% 2020 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 898		$ 898
Interest rate, stated percentage		3.45%		3.45%
4.10% notes due 2021 (4.10% 2021 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 998		$ 998
Interest rate, stated percentage		4.10%		4.10%
3.875% notes due 2021 (3.875% 2021 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 1,746		$ 1,746
Interest rate, stated percentage		3.875%		3.875%
3.625% notes due 2022 (3.625% 2022 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 747		$ 747
Interest rate, stated percentage		3.625%		3.625%
3.625% notes due 2024 (3.625% 2024 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 1,398		$ 0
Interest rate, stated percentage		3.625%
Debt instrument, redemption period	3 months
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 807		$ 781
Interest rate, stated percentage		5.50%		5.50%
4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 1,183		$ 1,144
Interest rate, stated percentage		4.00%		4.00%
6.375% notes due 2037 (6.375% 2037 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 899		$ 899
Interest rate, stated percentage		6.375%		6.375%
6.90% notes due 2038 (6.90% 2038 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 499		$ 499
Interest rate, stated percentage		6.90%		6.90%
6.40% notes due 2039 (6.40% 2039 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 996		$ 996
Interest rate, stated percentage		6.40%		6.40%
5.75% notes due 2040 (5.75% 2040 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 697		$ 697
Interest rate, stated percentage		5.75%		5.75%
4.95% notes due 2041 (4.95% 2041 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 596		$ 596
Interest rate, stated percentage		4.95%		4.95%
5.15% notes due 2041 (5.15% 2041 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 2,233		$ 2,233
Interest rate, stated percentage		5.15%		5.15%
5.65% notes due 2042 (5.65% 2042 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 1,244		$ 1,244
Interest rate, stated percentage		5.65%		5.65%
5.375% notes due 2043 (5.375% 2043 Notes) [Member]
Carrying values of long-term borrowings
Notes payable, noncurrent		$ 1,000		$ 1,000
Interest rate, stated percentage		5.375%		5.375%

Stockholders' equity (Details Textual) - USD ($) $ / shares in Units, $ in Billions	1 Months Ended					3 Months Ended		6 Months Ended
	Jul. 25, 2014	Jun. 06, 2014	Mar. 07, 2014	Mar. 05, 2014	Dec. 13, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Subsequent Event [Line Items]
Common stock, dividends declared per share (in usd per share)				$ 0.61	$ 0.61
Amount available for stock repurchases under a board approved stock repurchase plan								$ 1.6
Dividends paid per share (in usd per share)		$ 0.61	$ 0.61			$ 0.61	$ 0.47	$ 1.22	$ 0.94
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, dividends declared per share (in usd per share)	$ 0.61

Stockholders' equity (Details 1) - USD ($) $ in Millions	3 Months Ended
Stockholders' equity (Details 1) - USD ($) $ in Millions	Jun. 30, 2014	Mar. 31, 2014
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward]
Beginning balance, Foreign currency translation	$ (76)	$ (68)
Beginning balance, Cash flow hedges	(31)	(33)
Beginning balance, Available-for-sale securities	(3)	(43)
Beginning balance, Other	(16)	(17)
Beginning balance, AOCI	(126)	(161)
Other Comprehensive Income (Loss), before Tax [Abstract]
Foreign currency translation adjustments	9	(12)
Unrealized gains, Cash flow hedges	8	17
Unrealized gains, Available-for-sale securities	73	66
Unrealized gains, Other	0	1
Unrealized gains, AOCI	81	84
Reclassification adjustments to income, Foreign currency translation	0	0
Reclassification adjustments to income, Cash flow hedges	(48)	(14)
Reclassification adjustments to income, Available-for-sale securities	(40)	(2)
Reclassification adjustments to income, AOCI	(88)	(16)
Income taxes, Foreign currency translation	(2)	4
Income taxes, Cash flow hedges	15	(1)
Income taxes, Available-for-sale securities	(12)	(24)
Income taxes, Other	0	0
Income taxes, AOCI	1	(21)
Ending balance, Foreign currency translation	(69)	(76)
Ending balance, Cash flow hedges	(56)	(31)
Ending balance, Available-for-sale securities	18	(3)
Ending balance, Other	(16)	(16)
Ending balance, AOCI	$ (123)	$ (126)

Stockholders' equity (Details 2) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Stockholders' equity (Details 2) - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	$ 4,949	$ 4,595	$ 9,305	$ 8,746
Interest and other income, net	138	96	237	260
Interest expense, net	(282)	(241)	(541)	(504)
Income before income taxes	1,758	1,405	2,962	2,748
Tax expense	(211)	(147)	(342)	(56)
Net income	1,547	1,258	2,620	2,692
Cash Flow Hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Product sales	0	7	0	3
Interest and other income, net	48	12	62	(128)
Interest expense, net	0	(1)	0	(1)
Income before income taxes	48	18	62	(126)
Tax expense	(18)	(7)	(23)	46
Net income	30	11	39	(80)
Realized Gains and Losses on Available-for-sale Securities [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification out of Accumulated Other Comprehensive Income [Line Items]
Interest and other income, net	40	7	42	74
Tax expense	(15)	(3)	(16)	(28)
Net income	$ 25	$ 4	$ 26	$ 46

Fair value measurement Fair value measurement (Details 1) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance			$ 595
Ending balance	$ 610		610
Significant unobservable inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	596	$ 222	595	$ 221
Net changes in valuation	14	110	15	111
Ending balance	$ 610	$ 332	$ 610	$ 332

Fair value measurements (Details Textual) $ in Millions	1 Months Ended	3 Months Ended	6 Months Ended
Fair value measurements (Details Textual) $ in Millions	Mar. 31, 2011 USD ($) ContingentConsideration	Jun. 30, 2014 USD ($) payment	Jun. 30, 2014 USD ($) payment	Dec. 31, 2013 USD ($)
Business Acquisition [Line Items]
Length of time hedged in foreign currency contracts			3 years
Fair Value Measurement (Textual) [Abstract]
Aggregate fair value of long-term debt, including current portion		$ 35,600	$ 35,600	$ 33,500
Carrying value of long-term debt, including current portion		33,328	33,328	$ 32,128
BioVex Group Inc [Member]
Business Acquisition [Line Items]
Maximum additional consideration due contingent on milestones	$ 575
The number of payments that will potentially be made that each equal the largest potential contingent consideration payment \| ContingentConsideration	3
Largest potential contingent consideration payments	$ 125
Additional contingent consideration upon achievement of milestones	$ 200
Change in fair values of contingent consideration obligations		13
Assumed contingent consideration obligation		347	347
Onyx Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Change in fair values of contingent consideration obligations		1	2
Assumed contingent consideration obligation		$ 263	$ 263
Number of milestone payments \| payment		2	2
Contingent consideration arrangements, milestone payments		$ 150	$ 150
Other Government-related and Corporate Debt Securities [Member]
Business Acquisition [Line Items]
Investment maturity period			5 years

Derivative instruments (Details) - Cash flow hedge [Member] - Cross currency swap contracts [Member] € in Millions, £ in Millions, $ in Millions	Jun. 30, 2014 GBP (£)	Jun. 30, 2014 EUR (€)	Jun. 30, 2014 USD ($)
2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member]
Derivative [Line Items]
Notional amount		€ 675	$ 864
2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member] \| Interest rate received [Member]
Derivative [Line Items]
Interest rate	2.125%	2.125%	2.125%
2.125% euro denominated notes due 2019 (2.125% 2019 euro Notes) [Member] \| Interest rate paid [Member]
Derivative [Line Items]
Interest rate	2.60%	2.60%	2.60%
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member]
Derivative [Line Items]
Notional amount	£ 475		$ 748
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member] \| Interest rate received [Member]
Derivative [Line Items]
Interest rate	5.50%	5.50%	5.50%
5.50% pound sterling denominated notes due 2026 (5.50% 2026 pound sterling Notes) [Member] \| Interest rate paid [Member]
Derivative [Line Items]
Interest rate	5.80%	5.80%	5.80%
4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member]
Derivative [Line Items]
Notional amount	£ 700		$ 1,122
4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member] \| Interest rate received [Member]
Derivative [Line Items]
Interest rate	4.00%	4.00%	4.00%
4.00% pound sterling denominated notes due 2029 (4.00% 2029 pound sterling Notes) [Member] \| Interest rate paid [Member]
Derivative [Line Items]
Interest rate	4.30%	4.30%	4.30%

Derivative instruments (Details 1) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Derivative instruments (Details 1) - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	$ 8	$ 53	$ 25	$ 28
Foreign currency contracts [Member]
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	(13)	21	0	121
Cross currency swap contracts [Member]
Effective portion of the unrealized gain (loss) recognized in Other Comprehensive Income for our derivative instruments designated as cash flow hedges
Unrealized gain (loss) on derivative instruments recognized in Other Comprehensive Income, effective portion, net	$ 21	$ 32	$ 25	$ (93)

Derivative instruments (Details 2) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Derivative instruments (Details 2) - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Derivative Instruments Gain Loss [Line Items]
Product sales	$ 4,949	$ 4,595	$ 9,305	$ 8,746
Interest and other income, net	138	96	237	260
Interest expense, net	(282)	(241)	(541)	(504)
Income before income taxes	1,758	1,405	2,962	2,748
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Derivative Instruments Gain Loss [Line Items]
Product sales	0	7	0	3
Interest and other income, net	48	12	62	(128)
Interest expense, net	0	(1)	0	(1)
Income before income taxes	48	18	62	(126)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedge [Member]
Derivative Instruments Gain Loss [Line Items]
Income before income taxes	48	18	62	(126)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedge [Member] \| Foreign currency contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Product sales	0	7	0	3
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedge [Member] \| Cross currency swap contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Interest and other income, net	48	12	62	(128)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member] \| Cash flow hedge [Member] \| Forward interest rate contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Interest expense, net	$ 0	$ (1)	$ 0	$ (1)

Derivative instruments (Details 3) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Derivative instruments (Details 3) - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Foreign currency contracts [Member] \| Interest and other income, net [Member]
Location in the Condensed Consolidated Statements of Income and the amount of gain (loss) recognized in earnings for our derivative instruments not designated as hedging instruments
Amount of gain (loss) recognized in interest and other income, net	$ (14)	$ 11	$ (12)	$ (5)

Derivative instruments (Details 4) - USD ($) $ in Millions	Jun. 30, 2014	Dec. 31, 2013
Assets
Total derivative assets, fair value	$ 276	$ 246
Liabilities
Total derivative liabilities, fair value	150	272
Derivatives designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	275	246
Liabilities
Total derivative liabilities, fair value	149	269
Derivatives not designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	1	0
Liabilities
Total derivative liabilities, fair value	1	3
Cross currency swap contracts [Member] \| Other current assets/Other noncurrent assets [Member] \| Derivatives designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	214	193
Cross currency swap contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member] \| Derivatives designated as hedging instrument [Member]
Liabilities
Total derivative liabilities, fair value	1	4
Foreign currency contracts [Member] \| Other current assets/Other noncurrent assets [Member] \| Derivatives designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	31	53
Foreign currency contracts [Member] \| Other current assets [Member] \| Derivatives not designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	1	0
Foreign currency contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member] \| Derivatives designated as hedging instrument [Member]
Liabilities
Total derivative liabilities, fair value	82	104
Foreign currency contracts [Member] \| Accrued liabilities [Member] \| Derivatives not designated as hedging instrument [Member]
Liabilities
Total derivative liabilities, fair value	1	3
Interest rate swap contracts [Member] \| Other current assets/Other noncurrent assets [Member] \| Derivatives designated as hedging instrument [Member]
Assets
Total derivative assets, fair value	30	0
Interest rate swap contracts [Member] \| Accrued liabilities/Other noncurrent liabilities [Member] \| Derivatives designated as hedging instrument [Member]
Liabilities
Total derivative liabilities, fair value	$ 66	$ 161

Derivative instruments (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Derivative Instruments Gain Loss [Line Items]
Length of time hedged in foreign currency contracts			3 years
Interest expense, net [Member]
Derivative Instruments Gain Loss [Line Items]
Unrealized gain (loss) on the hedged debt	$ (63)	$ 113	$ (125)	$ 91
Unrealized gain (loss) on interest rate swaps	63	$ (113)	125	$ (91)
Foreign currency forward contracts [Member] \| Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative, notional amount	4,000		4,000		$ 4,000
Foreign currency forward contracts [Member] \| Not Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative, notional amount	878		878		999
Foreign currency option contracts [Member] \| Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative, notional amount	342		342		516
Foreign currency and cross currency swap contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months - losses	36		36
Forward interest rate contracts [Member]
Derivative Instruments Gain Loss [Line Items]
Amounts expected to be reclassified from AOCI into earnings over the next 12 months - losses	1		1
Interest rate swap [Member] \| Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative, notional amount	$ 2,250		$ 2,250		$ 4,400
Rate adjustment to LIBOR on interest rate swap agreements [Member] \| LIBOR [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative lower range variable interest rate	0.40%		0.40%		1.10%
Derivative higher range variable interest rate	0.60%		0.60%		2.00%

Subsequent event (Details) - Subsequent Event [Member] - Other Restructuring [Member] $ in Millions	Jul. 29, 2014 USD ($) staff
Subsequent Event [Line Items]
Total charges, percentage of cash outlay	40.00%
Minimum [Member]
Subsequent Event [Line Items]
Reduction in the number of staff by end of 2015 \| staff	2,400
Expected pre-tax accounting charges	$ 775
Accelerated depreciation and asset impairment charges	400
Charges resulting from staff reductions	$ 375
Maximum [Member]
Subsequent Event [Line Items]
Reduction in the number of staff by end of 2015 \| staff	2,900
Expected pre-tax accounting charges	$ 950
Accelerated depreciation and asset impairment charges	500
Charges resulting from staff reductions	$ 450

Fair value measurement (Details) - USD ($) $ in Millions	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012
Assets:
Total available-for-sale investments	$ 25,686		$ 22,363
Fair Value, Measurements, Recurring [Member]
Derivative Assets:
Interest rate swap contracts	30
Total assets	25,962		22,609
Derivative Liabilities:
Interest rate swap contracts	66		161
Contingent consideration obligations in connection with business combinations	610		595
Total liabilities	760		867
Fair Value, Measurements, Recurring [Member] \| Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	32		53
Derivative Liabilities:
Foreign currency contracts	83		107
Fair Value, Measurements, Recurring [Member] \| Cross currency swap contracts [Member]
Derivative Assets:
Foreign currency contracts	214		193
Derivative Liabilities:
Foreign currency contracts	1		4
Fair Value, Measurements, Recurring [Member] \| U.S. Treasury securities [Member]
Assets:
Total available-for-sale investments	2,889		4,730
Fair Value, Measurements, Recurring [Member] \| Other government-related debt securities - U.S. [Member]
Assets:
Total available-for-sale investments	961		1,079
Fair Value, Measurements, Recurring [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	1,564		1,546
Fair Value, Measurements, Recurring [Member] \| Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	5,163		3,676
Fair Value, Measurements, Recurring [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	5,373		3,760
Fair Value, Measurements, Recurring [Member] \| Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	574		390
Fair Value, Measurements, Recurring [Member] \| Residential mortgage-backed securities [Member]
Assets:
Total available-for-sale investments	1,740		1,460
Fair Value, Measurements, Recurring [Member] \| Other mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	1,874		1,511
Fair Value, Measurements, Recurring [Member] \| Money market mutual funds [Member]
Assets:
Total available-for-sale investments	3,328		3,366
Fair Value, Measurements, Recurring [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments	2,138		750
Fair Value, Measurements, Recurring [Member] \| Equity securities [Member]
Assets:
Total available-for-sale investments	82		95
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member]
Derivative Assets:
Interest rate swap contracts	0
Total assets	6,299		8,191
Derivative Liabilities:
Interest rate swap contracts	0		0
Contingent consideration obligations in connection with business combinations	0		0
Total liabilities	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	0		0
Derivative Liabilities:
Foreign currency contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Cross currency swap contracts [Member]
Derivative Assets:
Foreign currency contracts	0		0
Derivative Liabilities:
Foreign currency contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| U.S. Treasury securities [Member]
Assets:
Total available-for-sale investments	2,889		4,730
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other government-related debt securities - U.S. [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Residential mortgage-backed securities [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Money market mutual funds [Member]
Assets:
Total available-for-sale investments	3,328		3,366
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Quoted prices in active markets for identical assets (Level 1) [Member] \| Equity securities [Member]
Assets:
Total available-for-sale investments	82		95
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member]
Derivative Assets:
Interest rate swap contracts	30
Total assets	19,663		14,418
Derivative Liabilities:
Interest rate swap contracts	66		161
Contingent consideration obligations in connection with business combinations	0		0
Total liabilities	150		272
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	32		53
Derivative Liabilities:
Foreign currency contracts	83		107
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Cross currency swap contracts [Member]
Derivative Assets:
Foreign currency contracts	214		193
Derivative Liabilities:
Foreign currency contracts	1		4
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| U.S. Treasury securities [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other government-related debt securities - U.S. [Member]
Assets:
Total available-for-sale investments	961		1,079
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	1,564		1,546
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	5,163		3,676
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	5,373		3,760
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	574		390
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Residential mortgage-backed securities [Member]
Assets:
Total available-for-sale investments	1,740		1,460
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	1,874		1,511
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Money market mutual funds [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments	2,138		750
Fair Value, Measurements, Recurring [Member] \| Significant other observable inputs (Level 2) [Member] \| Equity securities [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member]
Derivative Assets:
Interest rate swap contracts	0
Total assets	0		0
Derivative Liabilities:
Interest rate swap contracts	0		0
Contingent consideration obligations in connection with business combinations	610	$ 596	595	$ 332	$ 222	$ 221
Total liabilities	610		595
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Foreign currency contracts [Member]
Derivative Assets:
Foreign currency contracts	0		0
Derivative Liabilities:
Foreign currency contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Cross currency swap contracts [Member]
Derivative Assets:
Foreign currency contracts	0		0
Derivative Liabilities:
Foreign currency contracts	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| U.S. Treasury securities [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other government-related debt securities - U.S. [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other government-related debt securities - Foreign and other [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Corporate debt securities - Financial [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Corporate debt securities - Industrial [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Corporate debt securities - Other [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Residential mortgage-backed securities [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other mortgage- and asset-backed securities [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Money market mutual funds [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Other short-term interest-bearing securities [Member]
Assets:
Total available-for-sale investments	0		0
Fair Value, Measurements, Recurring [Member] \| Significant unobservable inputs (Level 3) [Member] \| Equity securities [Member]
Assets:
Total available-for-sale investments	$ 0		$ 0